Schedule Update - effective 1 July 2008 (text extract)

This is the text extract for Schedule Update - effective 1 July 2008, browse documents here.

Pharmaceutical Management Agency

Update

New Zealand Pharmaceutical Schedule

Effective 1 July 2008 Cumulative for May, June, and July 2008

Contents

Summary of PHARMAC decisions effective 1 July 2008 ................................. 3 Various restrictions removed from some Alimentary Tract and Metabolism medicines ........................................................................... 6 Hydroxocobalamin – PSO availability ............................................................. 7 Omeprazole................................................................................................... 7 Postinor-1 – change in quantity available on prescription ............................. 7 Change of contact details for Growth Hormone applications ....................... 7 Glyceryl trinitrate sublingual tablets – fully subsidised .................................. 8 Tender News .................................................................................................. 8 Looking Forward ........................................................................................... 8 Sole Subsidised Supply products cumulative to July 2008 ............................. 9 New Listings ................................................................................................ 15 Changes to Restrictions ............................................................................... 18 Changes to Subsidy and Manufacturer’s Price............................................. 25 Changes to General Rules............................................................................ 31 Changes to PSO........................................................................................... 32 Changes to Sole Subsidised Supply ............................................................. 32 Delisted Items ............................................................................................. 33 Items to be Delisted .................................................................................... 36 Section H changes to Part II ........................................................................ 38 Section H changes to Part IV ....................................................................... 49 Index ........................................................................................................... 50

Summary of PharmaC decisions

effeCtive 1 July 2008 New listing (pages 15-17) • Omeprazole (Dr Reddy’s Omeprazole) cap 10 mg, 20 mg and 40 mg, 30 capsule bottles • Calcium (Calcium Sandoz, Calsource) tab 1 g effervescent • Iron polymaltose (Ferrum H) inj 50 per ml, 2 ml • Glyceryl trinitrate (Lycinate) tab 600 µg - available on a PSO • Zinc and castor oil (PSM) ointment • Paracetamol oral liquid 120 mg per 5 ml (Paracare Junior) and oral liquid 250 mg per 5 ml (Paracare Double Strength) • Nortripytline tab 25 mg, 250 tablet pack size • Budesonide with eformoterol aerosol inhaler 100 µg with eformoterol fumarate 6 µg and aerosol inhaler 200 µg with eformoterol fumarate 6 µg (Vannair) – Special Authority for Subsidy • Gluten free pasta garlic and parsley shells (Orgran) – Special Authority for subsidy Changes to restriction (pages 18-24) • Budesonide (Entocort CIR) cap 3 mg – amended Special Authority criteria • Olsalazine (Dipentum) tab 500mg and cap 250 mg – removal of Retail pharmacy -Specialist • Sodium cromoglycate (Nalcrom) cap 100 mg – removal of Hospital pharmacy [HP3] Specialist • Mebeverine hydrochloride (Colofac) tab 135 mg – removal of Retail pharmacy - Specialist • Misoprostol (Cytotec) tab 200 µg - removal of Retail pharmacy - Specialist • Ranitidine hydrochloride (Peptisoothe) oral liquid 150 mg per 10 ml – removal of endorsement criteria • Ursodeoxycholic acid (Actigall) cap 300 mg - amended Special Authority criteria • Benzydamine hydrochloride (Difflam) soln 0.15% - removal of Retail pharmacy – Specialist prescription • Alfacalcidol (One-Alpha) cap 0.25 µg,1 µg and oral drops 2 µg per ml removal of Retail pharmacy - Specialist • Alpha tocopheryl acetate (Micelle E) water solubilised soln 156 iu/ml, with calibrated dropper - amended Special Authority criteria • Calcitriol (Calcitriol-AFT) cap 0.25 µg and 0.5 µg and (Rocaltrol solution) oral liq 1 µg per ml - removal of Retail pharmacy - Specialist

Summary of PharmaC decisions – effective 1 July 2008 (continued) • Calcium polystyrene sulphonate (Calcium Resonium) powder – addition of OP • Sodium polystyrene sulphonate (Resonium-A) powder – addition of OP • Levonorgestrel (Postinor-1) tab 1.5 mg – Maximum of 2 tabs per prescription • Ziprasidone – change to endorsement criteria Decreased subsidy (pages 25-30) • Omeprazole (Omezol) cap 10 mg, 20 mg and 40 mg • Gliclazide (Apo-Gliclazide) tab 80 mg • Ursodeoxycholic acid (Actigall) cap 300 mg • Triamcinolone acetonide (Oracort) 0.1% in dental paste • Clotrimazole (Clomazol) crm 1% • Miconazole nitrate (Multichem) crm 2% • Emulsifying ointment (AFT) ointment BP • Salicylic acid (David Craig) powder • Sulphur (PSM) precipitated • Sunscreen, proprietary crm (Hamilton sunscreen, Aquasun Oil Free Faces SPF 30+) and lotn (Aquasun Sensitive SPF 30+, Aquasun 30+) • Condoms 52 mm (Marquis Supalite) • Condoms 52 mm extra strength (Marquis Protecta) • Condoms 54 mm shaped (Lifestyles Flared) • Condoms 56 mm shaped (Durex Confidence) • Pamidronate disodium (Pamisol) inj 3mg per ml, 5 ml, inj 3 mg per ml, 10ml and inj 6 mg per ml, 10 ml • Desmopressin (Desmopressin-PH&T) nasal spray 10 µg per dose • Cefuroxime axetil (Zinnat) tab 250 mg • Fluconazole (Pacific) cap 50 mg, 150 mg and 200 mg • Terbinafine (Apo-Terbinafine) tab 250 mg • Norfloxacin (Arrow-Norfloxacin) tab 400 mg • Metoclopramide hydrochloride (Pfizer) inj 5 mg per ml, 2 ml • Pergolide (Permax) tab 0.25 mg and 1 mg • Calcium folinate (Calcium Folinate Ebewe) inj 50 mg • Brimodine tartarate (AFT) eye drops 0.2% • Glycerol (Midwest) liquid • Methyl hydroxybenzoate (PSM) powder

Summary of PharmaC decisions – effective 1 July 2008 (continued) • Methylcellulose (Midwest) powder • Sodium bicarbonate powder (Biomed, David Craig) increased subsidy (pages 25-30) • Betamethasone valerate crm 0.1% (Beta Cream) oint 0.1% (Beta Ointment) • Salbutamol with ipratropium bromide (Combivent) aerosol inhaler 100 µg with ipratropium bromide, 20 µg per dose • Aminoacid formula without methionine powder (XMET Maxamum) • Aminoacid formula without valine, leucine and isoleucine powder (MSUD Maxamaid and MSUD Maxamum) • Aminoacid formula with minerals without phenylalanine (Metabolic Mineral Mixture) powder

6 Pharmaceutical Schedule - Update News

Various restrictions removed from some Alimentary Tract and Metabolism medicines

Some medicines in the Alimentary Tract and Metabolism therapeutic group of the Pharmaceutical Schedule have had “Retail pharmacy – Specialist”, “Hospital pharmacy – Specialist” and “Retail pharmacy – Specialist prescription” restrictions removed. The medicines affected are: • alfacalcidol • benzydamine hydrochloride; • calcitriol; • mebeverine hydrochloride; • misoprostol; • olsalazine; • pancreatic enzyme; and • sodium cromoglycate. This means that all of these medicines will be subsidised when prescribed by any practitioner with the appropriate scope of practice, as determined by the appropriate regulatory body. The Special Authority restrictions applying to some medicines have had the applicant type amended from various specialists only, to any relevant practitioner. The medicines affected are: • alpha tocopheryl acetate. • budesonide; and • ursodeoxycholic acid. The endorsement criteria for ranitidine hydrochloride oral liquid have been removed. See pages 18-20 for further details of these restriction changes.

Pharmaceutical Schedule - Update News

Hydroxocobalamin – PSO availability

Hydroxocobalamin 1 mg per ml, 1 ml injection has been added to the Practitioner’s Supply Order (PSO) list from 1 July 2008. Practitioners will be able to order a maximum of 6 injections on each PSO. There are now two fully funded brands available - Neo-B12 and ABM Hydroxocobalamin. See page 32 for details.

Omeprazole

Further to our notification of 29 April 2008, Dr Reddy’s Omeprazole bottle packs of 30 capsules are now available and will be fully subsidised from 1 July 2008. This pack size and packaging type is in addition to the currently available blister pack of 28 capsules. Both pack sizes and packaging types will be listed and fully subsidised throughout the Sole Subsidised Supply period as previously notified. The subsidy of Omezol will be reduced to the same level as Dr Reddy’s Omeprazole from 1 July 2008. See page 25 for further details.

Postinor-1 – change in quantity available on prescription

The maximum quantity available on a prescription has been increased from 1 to 2 tablets from1 July 2008. When Postinor-1 was listed in the Pharmaceutical Schedule in June 2008, there was a maximum quantity subsidised per prescription of 1 tablet. This is the dose that is required for use as an emergency contraceptive. However, some patients may vomit and may need a second dose. This amendment allows for that.

Change of contact details for Growth Hormone applications

From 1 July 2008 Growth Hormone applications are to be sent to Kyle Reid NZGHC Co-ordinator, PHARMAC PO Box 10-254 Wellington Tel: (04) 916 7561 Fax: (04) 460 4995 email: kyle.reid@pharmac.govt.nz

Glyceryl trinitrate sublingual tablets -fully subsidised

From 1 July 2008 the Lycinate brand of glyceryl trinitrate 600 μg sublingual tablets will be listed fully subsidised in the Pharmaceutical Schedule. They will also be available on a Practitioners Supply Order (PSO) with a maximum quantity of 100 tablets per PSO. See page 15 for details.

tender News

Sole Subsidised Supply changes – effective 1 August 2008

Chemical Name Dextrose Glyceryl trinitrate Glyceryl trinitrate Prazosin hydrochloride Prazosin hydrochloride Prazosin hydrochloride Presentation; Pack size Inj 50%, 10 ml; 5 inj TDDS 5 mg; 30 patch TDDS 10 mg; 30 patch Tab 1 mg; 100 tab Tab 2 mg; 100 tab Tab 5 mg; 100 tab Sole Subsidised Supply brand (and supplier) Biomed (Biomed) Nitroderm TTS 5 (Novartis) Nitroderm TTS 10 (Novartis) Apo-Prazo (Apotex) Apo-Prazo (Apotex) Apo-Prazo (Apotex)

looking forward

This section is designed to alert both pharmacists and prescribers to possible future changes. It may assist pharmacists to manage stock levels and keep prescribers up-to-date with proposals to change the Pharmaceutical Schedule. Possible decisions for implementation 1 august 2008 • Adalimumab inj 40 mg per 0.8 ml prefilled pen (HumiraPen) – new listing • Condoms 49 mm (Marquis Tantiliza), 52 mm (Marquis Selecta, Marquis Sensolite), 53 mm (Marquis Titillata, Marquis Black), 55 mm (Marquis Protecta), and 60 mm (Shield XL) • Aripiprazole (Abilify) tab 10 mg, 15 mg, 20 mg and 30 mg – new listing with restrictions • Bee venom allergy treatment and wasp venom allergy treatment – amended Special Authority criteria • For August Tender changes see the Tender Notification fax which will be sent out and posted on our website at www.pharmac.govt.nz at the end of June.

Sole Subsidised Supply Products – cumulative to July 2008

Generic Name

Alprazolam

Presentation

Tab 250 µg Tab 500 µg Tab 1 mg Inj 10 mg per ml, 1 ml Cap 250 mg & 500 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Tab 100 mg Tab 100 mg Tab 50 mg & 100 mg Inj 600 µg, 1 ml Inj 1200 µg, 1 ml Tab 500 mg Metered aqueous nasal spray 50 µg Metered aqueous nasal spray 100 µg Scalp app 0.1% Tab 5 mg Inj 0.5%, 4 ml Inj 0.5%, 8% glucose, 4 ml Lotion BP Crm, aqueous, BP Cap 0.25 µg & 0.5 µg Tab 12.5 mg, 25 mg & 50 mg Cap 250 mg Grans for oral liq 125 mg per 5 ml Crm BP Eye drops 0.5% Eye oint 1% Handrub 1% with ethanol 70% Mouthwash 0.2% Tab 25 mg Tab 250 mg Grans for oral liq 125 mg per 5 ml Crm 0.05% Vaginal crm 1% with applicator(s) Tab 15 mg, 30 mg & 60 mg Tab 500 µg Sach 5 g Inj 150 mg

Brand Name Expiry Date*

Arrow-Alprazolam Arrow-Alprazolam Arrow-Alprazolam Mayne Apo-Amoxi Ranbaxy Amoxicillin Ranbaxy Amoxicillin Apo-Ascorbic Acid Ethics Aspirin EC Loten AstraZeneca AstraZeneca Arrow-Azithromycin Alanase Alanase Beta Scalp Lax-Tab Marcain Isobaric Marcain Heavy ABM ABM Calcitriol-AFT Apo-Captopril Ranbaxy Cefaclor Ranbaxy Cefaclor PSM Chlorsig Chlorsig Orion Orion Hygroton Klamycin Klacid Dermol Clomazol PSM Colgout Colestid Colistin-Link 2010

Apomorphine hydrochloride Amoxycillin

2009 2010 2009 2009 2010 2009 2009 2009 2009 2009 2010 2010 2009 2009 2010 2010 2010 2009 2009 2009 2010 2009 2010 2010 2010 2010 2010

Ascorbic acid Aspirin Atenolol Atropine sulphate Azithromycin Beclomethasone dipropionate Betamethasone valerate Bisacodyl Bupivicaine hydrochloride Calamine Calcitriol Captopril Cefaclor monohydrate Cetomacrogol Chloramphenicol Chlorhexidine gluconate Chlorthalidone Clarithromycin Clobetasol propionate Clotrimazole Codeine phosphate Colchicine Colestipol hydrochloride Colistin sulphomethate

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 9

Sole Subsidised Supply Products – cumulative to July 2008

Generic Name

Compound electrolytes Cyclizine hydrochloride Cyclophosphamide Cyproterone acetate Dantrolene sodium Desferrioxamine mesylate Dexamethasone sodium phosphate Dexamphetamine sulphate Dextrose with electrolytes

Presentation

Powder for soln for oral use Tab 50 mg Tab 50 mg Tab 50 mg Cap 25 mg & 50 mg Inj 500 mg Inj 4 mg per ml, 1 ml Inj 4 mg per ml, 2 ml Tab 5 mg Oral soln with electrolytes

Brand Name Expiry Date*

Enerlyte Nausicalm Cycloblastin Siterone Dantrium Mayne Mayne PSM Pedialyte – Plain Pedialyte – Bubblegum Pedialyte – Fruit Apo-Diclo Apo-Diclo SR Videx EC Apo-Doxazosin m-Enalapril Mayne Cafergot New Zealand Medical and Scientific Brevinor 21 Brevinor 1/21 Brevinor 1/28 Vepesid Ferodan Staphlex AFT AFT Ultraproct Ultraproct 2009 2010 2009 2010 2009 2010 2009 2009 2010 2009 2010 2010

Dicloflenac sodium Didanosine (DDI) Doxazosin mesylate Enalapril Ergometrine maleate Ergotamine tartrate with caffeine Ethinyloestradiol Ethinyloestradiol with norethisterone

Tab EC 25 mg & 50 mg Tab long-acting 75 mg & 100 mg Cap 125 mg, 200 mg, 250 mg & 400 mg Tab 2 mg & 4 mg Tab 5 mg, 10 mg & 20 mg Inj 500 µg per ml, 1 ml Tab 1 mg with caffeine 100 mg Tab 10 µg Tab 35 µg with norethisterone 500 µg Tab 35 µg with norethisterone 1 mg Tab 35 µg with norethisterone 1 mg and 7 inert tab Cap 50 mg & 100 mg Oral liq 150 mg per 5 ml Cap 250 mg & 500 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Oint 950 µg, with fluocortolone pivalate 920 µg, and cinchocaine hydrochloride 5 mg per g Suppos 630 µg, with fluocortolone pivalate 610 µg, and cinchocaine hydrochloride 1 mg Eye drops 0.1% Cap 20 mg Tab disp 20 mg, scored

2009 2009 2010 2009 2009 2009 2009 2010

Etoposide Ferrous sulphate Flucloxacillin sodium

Fluocortolone caproate with fluocortolone pivalate and cinchocaine

2010

Fluorometholone Fluoxetine hydrochloride

Flucon Fluox Fluox

2009 2010

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 10

Sole Subsidised Supply Products – cumulative to July 2008

Generic Name

Folic Acid Fusidic acid Gentamicin sulphate Haloperidol

Presentation

Tab 0.8 mg & 5 mg Crm 2% & Oint 2% Inj 40 mg per ml, 2 ml Oral liq 2 mg per ml Tab 500 µg, 1.5 mg & 5 mg Inj 5 mg per ml, 1 ml Inj 10 iu per ml, 5 ml Tab 5 mg & 20 mg Rectal foam 10%, CFC-Free Scalp lotn 0.1% Oral liq 100 mg per 5 ml, 200 ml Tab 10 mg & 25 mg Tab 2.5 mg Aqueous nasal spray, 0.03% Nebuliser soln, 250 µg per ml, 1 ml Nebuliser soln, 250 µg per ml, 2 ml Tab long-acting 60 mg Cap 10 mg Cap 20 mg Cap 100 mg Oral liq 10 g per 15 ml Eye drops 0.25% & 0.5% Cap 50 mg with benserazide 12.5 mg Tab dispersible 50 mg with benserazide 12.5 mg Cap 100 mg with benserazide 25 mg Cap long-acting 100 mg with benserazide 25 mg Cap 200 mg with benserazide 50 mg Inj 0.5%, 5 ml Inj 1%, 5 ml Inj 1%, 20 ml Crm 2.5% with prilocaine 2.5%; 30 g OP Crm 2.5% with prilocaine 2.5%; 5 g Tab 5 mg, 10 mg & 20 mg Tab 2 mg Tab 10 mg Oral liq 1 mg per ml

Brand Name Expiry Date*

Apo-Folic Acid Foban Pfizer Serenace Serenace Serenace AstraZeneca Douglas Colifoam Locoid Fenpaed Tofranil Napamide Apo-Ipravent Ipratripium Steri-Neb Ipratripium Steri-Neb Duride Isotane 10 Isotane 20 Sporanox Duphalac Betagan Madopar 62.5 Madopar Dispersible Madopar 125 Madopar HBS Madopar 250 Xylocaine Xylocaine Xylocaine EMLA EMLA Arrow-Lisinopril Nodia Loraclear Hayfever Relief Lorapaed Ativan 2009 2010 2010 2010 2009 2010 2009 2010 2009 2009 2009 2009 2010 2010 2009 2009 2010

Heparinised saline Hydrocortisone Hydrocortisone acetate Hydrcortisone butyrate Ibuprofen Imipramine hydrochloride Indapamide Ipratropium bromide

Isosorbide mononitrate Isotretinoin Itraconazole Lactulose Levobunolol Levodopa with benserazide

2009 2009 2010 2010 2010 2009

Lignocaine hydrochloride

Lignocaine with prilocaine

2010

Lisinopril Loperamide hydrochloride Loratadine

Lorazepam

Tab 1 mg & 2.5 mg

2009

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 11

Sole Subsidised Supply Products – cumulative to July 2008

Generic Name

Magnesium sulphate Malathion Maldison Maprotiline hydrochloride Medroxyprogesterone acetate Mesalazine Metformin hydrochloride Methadone hydrochloride Methotrexate Methylphenidate hydrochloride

Presentation

Inj 49.3% Liq 0.5% Shampoo 1% Tab 25 mg & 75 mg Tab 2.5 mg, 5 mg, 10 mg, 100 mg & 200 mg Enema 1 g per 100 ml Tab 500 mg & 850 mg Tab 5 mg Powder 1 g Tab 2.5 mg & 10 mg Tab long-acting 20 mg Tab 5 mg & 20 mg Tab 10 mg Tab 4 mg & 100 mg Crm 0.1% and oint 0.1% Inj 40 mg per ml, 1 ml Inj 62.5 mg per ml, 1 ml Inj 500 mg & 1 g Tab long-acting 200 mg Cap 250 mg Tab 2.5 mg & 5 mg Tab 200 µg Tab 150 mg & 300 mg Oral liq 1 mg per ml Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml Inj 5 mg per ml, 1 ml Inj 15 mg per ml, 1 ml Cap long-acting 10 mg, 30 mg, 60 mg, 100 mg & 200 mg Tab immediate release 10 mg & 20 mg Inj 80 mg per ml, 1.5 ml & 5 ml Tab 40 mg & 80 mg Tab 50 mg Tab 250 mg Tab 500 mg Tab 275 mg

Brand Name Expiry Date*

Mayne Derbac M A-Lices Ludiomil Provera Pentasa Arrow-Metformin Methatabs AFT Methoblastin Rubifen SR Rubifen Rubifen Medrol Advantan Solu-Medrol Solu-Medrol Solu-Medrol Slow-Lopressor Metopirone Gutron Cytotec Apo-Moclobemide RA-Morph RA-Morph RA-Morph RA-Morph Mayne Mayne m-Eslon Sevredol Mayne Apo-Nadolol ReVia Noflam 250 Noflam 500 Sonaflam 2009 2010 2010 2009 2010 2009 2010 2010 2009 2010 2009 2009 2010 2009 2009 2009

Methylprednisolone Methylprednisolone aceponate Methylprednisolone sodium succinate Metoprolol tartrate Metyrapone Midodrine Misoprostol Moclobemide Morphine hydrochloride

2009 2009 2009

2009 2009 2009 2009 2009 2009

Morphine sulphate

2009

Morphine tartrate Nadolol Naltrexone hydrochloride Naproxen Naproxen sodium

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 12

Sole Subsidised Supply Products – cumulative to July 2008

Generic Name

Neostigmine Nevirapine Nicotinic acid Nifedipine Norethisterone Nystatin

Presentation

Inj 2.5 mg per ml, 1 ml Oral suspension 10 mg per ml Tab 50 mg & 500 mg Tab long-acting 20 mg Tab 350 µg Cap 500,000 u Tab 500,000 u Vaginal crm 100,000 u per 5 g with applicators Tab 4 mg & 8 mg Tab disp 4 mg & 8 mg Tab 5 mg Oral liq 5 mg per 5 ml Inj 10 mg per ml, 1 ml and 2 ml Oral liq 5 mg per 5 ml Inj 5 iu per ml, 1 ml Inj 10 iu per ml, 1 ml Inj 5 iu with ergometrine maleate 500 µg per ml, 1 ml Tab 20 mg Tab 40 mg

Brand Name Expiry Date*

AstraZeneca Viramune Suspension Apo-Nicotinic Acid Nyefax Retard Noriday 28 Nilstat Nilstat Nilstat Zofran Zofran Zydis Apo-Oxybutynin Apo-Oxybutynin OxyNorm OxyNorm Syntocinon Syntocinon Syntometrine Dr Reddy’s Pantoprazole Dr Reddy’s Pantoprazole Laci-Lube Loxamine Pexsig AFT AFT Cilicaine VK Cilicaine VK Prefrin Span-K MDS Quick Card Apo-Pyridoxine Q 200 Q 300 Peptisoothe Mycobutin Arrow-Roxithromycin 2010 2009 2009 2009 2009 2010 2009 2010 2010 2010 2009

Ondansetron Oxybutynin Oxycodone hydrochloride Oxytocin

Pantoprazole

2010

Paraffin liquid with soft white paraffin Paroxetine hydrochloride Perhexiline maleate Phenoxymethylpenicillin (Penicillin V)

Eye oint with soft white paraffin Tab 20 mg Tab 100 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Cap potassium salt 250 mg Cap potassium salt 500 mg Eye drops 0.12% Tab long-acting 600 mg Cassette Tab 50 mg Tab 200 mg Tab 300 mg Oral liq 150 mg per 10 ml Cap 150 mg Tab 150 mg & 300 mg

2010 2010 2009 2010

Phenylephrine hydrochloride Potassium chloride Pregnancy tests - HCG urine Pyridoxine hydrochloride Quinine sulphate Ranitidine hydrochloride Rifabutin Roxithromycin

2010 2009 2009 2009 2009 2010 2010 2009

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 13

Sole Subsidised Supply Products – cumulative to July 2008

Generic Name

Salbutamol

Presentation

Nebuliser soln 1 mg per ml, 2.5 ml Nebuliser soln 2 mg per ml, 2.5 ml Oral liq 2 mg per 5 ml Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg Tab 5 mg Inj 0.9%, 5 ml & 10 ml Grans eff 4 g sachets Nasal spray 4% Tab 500 mg Tab EC 500 mg Liq Tab 10 mg Tab 50 mg Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g Inj 1 mg per ml, 1 ml Inj 1 mg per ml, 2 ml Tab (BPC cap strength) Tab, strong, BPC Purified for injection 20 ml

Brand Name Expiry Date*

Asthalin Asthalin Salapin Duolin Apo-Selegiline AstraZeneca Ural Rex Salazopyrin Salazopyrin EN Midwest Apo-Timol Apo-Thiamine Kenacomb 2009 2010 2009 2009 2009 2010 2009 2009 2010 2009 2009 2009

Salbutamol with ipratropium bromide Selegiline hydrochloride Sodium chloride Sodium citro-tartrate Sodium cromoglycate Sulphasalazine Syrup (pharmaceutical grade) Timolol maleate Thiamine hydrochloride Triamcinolone acetonide with gramicidin, neomycin and nystatin Vincristine sulphate Vitamins Vitamin B complex Water There are no additions for July.

Mayne Mayne Healtheries Apo-B-Complex Multichem

2009 2009 2009 2009

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 14

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings

Effective 1 July 2008

27 OMEPRAZOLE ❋ Cap 10 mg ............................................................................... 2.14 ❋ Cap 20 mg ............................................................................... 3.05 ❋ Cap 40 mg ............................................................................... 3.59 37 CALCIUM ❋ Tab eff 1 g................................................................................. 6.54 IRON POLYMALTOSE Inj 50 mg per ml, 2 ml ............................................................ 20.95 GLYCERYL TRINITRATE ❋ Tab 600 µg – Up to 100 tab available on a PSO ........................ 8.00 ZINC AND CASTOR OIL Oint BP...................................................................................... 5.11 PARACETAMOL ❋‡ Oral liq 120 mg per 5 ml ......................................................... 6.80 a) Up to 200 ml available on a PSO b) Not in combination ❋‡ Oral liq 250 mg per 5 ml ......................................................... 7.00 a) Up to 100 ml available on a PSO b) Not in combination 107 147 NORTRIPTYLINE HYDROCHLORIDE Tab 25 mg .............................................................................. 17.45 250 ✔ Norpress 30 30 30 ✔ Dr Reddy’s Omeprazole ✔ Dr Reddy’s Omeprazole ✔ Dr Reddy’s Omeprazole ✔ Calcium Sandoz ✔ Calsource ✔ Ferrum H ✔ Lycinate ✔ PSM ✔ Paracare Junior ✔ Paracare Double Strength

37 60 65 104

5 100 OP 500 g 1,000 ml 1,000 ml

BUDESONIDE WITH EFORMOTEROL – Special Authority see SA0838– Retail pharmacy Aerosol inhaler 100 µg with eformoterol fumarate 6 µg ............ 55.00 120 dose OP ✔ Vannair Aerosol inhaler 200 µg with eformoterol fumarate 6 µg ............ 60.00 120 dose OP ✔ Vannair GLUTEN FREE PASTA – Special Authority see SA0722– Hospital pharmacy [HP3] Garlic and Parsley Shells .......................................................... 2.00 250 g OP (2.63)

177

Orgran

Effective 1 June 2008

35 HYDROXOCOBALAMIN ❋ Inj 1 mg per ml, 1 ml ................................................................. 9.21 HEPARINISED SALINE ❋ Inj 100 iu per ml, 2 ml ............................................................... 8.30 3 ✔ ABM Hydroxocobalamin ✔ Hospira S29

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings - effective 1 June 2008 (continued)

54 70 LOSARTAN – Special Authority see SA0911 – Retail Pharmacy ❋ Tab 25 mg .............................................................................. 20.31 CONDOMS ❋ 49mm - Up to 144 dev available on a PSO ................................ 1.11 ❋ 49mm - Up to 144 dev available on a PSO ............................... 13.36 ❋ 53mm (chocolate) - Up to 144 dev available on a PSO............. 13.36 ❋ 53mm (strawberry) - Up to 144 dev available on a PSO ........... 13.36 ❋ 55mm - Up to 144 dev available on a PSO ................................. 1.11 ❋ 55mm - Up to 144 dev available on a PSO .............................. 13.36 ❋ 53mm extra strength - Up to 144 dev available on a PSO ........... 1.11 ❋ 53mm extra strength - Up to 144 dev available on a PSO ......... 13.36 LEVONORGESTREL ❋ Tab 1.5 mg ............................................................................ 12.50 a) Maximum of 1 tab per prescription b) Up to 5 tab available on a PSO OESTRADIOL VALERATE ❋ Tab 1 mg .................................................................................. 8.24 LAMOTRIGINE ▲ Tab dispersible 25 mg ............................................................. 19.38 ▲ Tab dispersible 50 mg ............................................................. 32.97 ▲ Tab dispersible 100 mg ........................................................... 56.91 RIZATRIPTAN BENZOATE Wafer 10 mg ........................................................................... 25.32 SALBUTAMOL Aerosol inhaler, 100 µg per dose CFC free – Up to 1000 dose available on a PSO ...................................... 3.80 28 12 144 144 144 12 144 12 144 1 ✔ Cozaar ✔ Gold Knight ✔ Gold Knight ✔ Gold Knight ✔ Gold Knight ✔ Gold Knight ✔ Gold Knight ✔ Gold Knight ✔ Gold Knight

✔ Postinor-1

79 110

56 56 56 56 3

✔ Progynova

✔ Logem ✔ Logem ✔ Logem ✔ Maxalt Melt

112 147

200 dose OP ✔ Respigen

167 168 168

ORAL SUPPLEMENT 1KCAL/ML – Special Authority see SA0583 – Hosptial pharmacy [HP3] Powder (vanilla) sachet 54 g ..................................................... 6.91 10 ✔ Fortisip Powder DIABETIC ENTERAL FEED 1KCAL/ML – Special Authority see SA0594 – Hospital Pharmacy [HP3] Liquid ........................................................................................ 7.50 1000 ml OP ✔ Glucerna Select RTH ORAL FEED 1KCAL / ML – Special Authority see SA0594 – Hospital Pharmacy [HP3] Liquid (vanilla)........................................................................... 1.88 250 ml OP ✔ Glucerna Select

Effective 1 May 2008

31 INSULIN PEN NEEDLES – Maximum of 100 dev per prescription ❋ 29 g x 12.7 mm ...................................................................... 11.75 ❋ 31 g x 6 mm ........................................................................... 11.75 ❋ 31 g x 8 mm ........................................................................... 11.75 100 100 100 ✔ ABM ✔ ABM ✔ ABM

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings - effective 1 May 2008 (continued)

32 INSULIN SYRINGES, DISPOSABLE WITH ATTACHED NEEDLE – Maximum of 100 dev per prescription ❋ Syringe 0.3 ml with 29 g × 12.7 mm needle ........................... 14.45 100 ✔ ABM ❋ Syringe 0.3 ml with 31 g × 8 mm needle ................................ 14.45 100 ✔ ABM ❋ Syringe 0.5 ml with 29 g × 12.7 mm needle ........................... 14.45 100 ✔ ABM ❋ Syringe 0.5 ml with 31 g × 8 mm needle ................................ 14.45 100 ✔ ABM ❋ Syringe 1 ml with 29 g × 12.7 mm needle .............................. 14.45 100 ✔ ABM ❋ Syringe 1 ml with 31 g × 8 mm needle ................................... 14.45 100 ✔ ABM CONDOMS ❋ 53 mm (chocolate) .................................................................... 1.11 ❋ 53 mm (strawberry) .................................................................. 1.11 VALACICLOVIR Tab 500 mg .......................................................................... 163.80 12 12 30 ✔ Gold Knight ✔ Gold Knight ✔ Valtrex ✔ Norvir ✔ Efexor XR

91 95 108

RITONAVIR – Special Authority see SA0779 on page 93 – Hospital pharmacy [HP1] Cap 100 mg .......................................................................... 121.27 84 VENLAFAXINE – Special Authority see SA0789 below – Retail pharmacy Cap 37.5 mg ........................................................................... 18.64 28

continued...

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions

Effective 1 July 2008

24 BUDESONIDE Cap 3 mg – Special Authority see SA0913 0698 – Retail pharmacy................................................................. 166.50 90 ✔ Entocort CIR ➽ SA0913 0698 Special Authority for Subsidy Initial application only from any relevant practitioner a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months for applications meeting the following criteria: Both: 1. Mild to moderate ileal, ileocaecal or proximal Crohn’s disease; and 2. Any of the following: 2.1 Diabetes; or 2.2 Cushingoid habitus; or 2.3 Osteoporosis where there is significant risk of fracture; or 2.4 Severe acne following treatment with conventional corticosteroid therapy. Renewal only from any relevant practitioner a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment. OLSALAZINE – Retail pharmacy-Specialist Tab 500 mg ............................................................................ 59.86 Cap 250 mg ........................................................................... 31.51 SODIUM CROMOGLYCATE Cap 100 mg – Hospital pharmacy [HP3]-Specialist .................. 89.21 MEBEVERINE HYDROCHLORIDE – Retail pharmacy-Specialist ❋ Tab 135 mg ........................................................................... 10.72 (25.73) MISOPROSTOL – Retail pharmacy-Specialist ❋ Tab 200 µg ............................................................................ 52.70 100 100 100 90 Colofac 120 ✔ Cytotec ✔ Dipentum ✔ Dipentum ✔ Nalcrom

25 26

26 26

RANITIDINE HYDROCHLORIDE – Only on a prescription ❋ Oral liq 150 mg per 10 ml – Subsidy by endorsement ................ 7.95 300 ml ✔ Peptisoothe Oral liquid is subsidized for patients: 1. with oesophageal stricture, or 2. in terminal care, or 3. who are either too young or too old to swallow conventional tablets and the prescription is endorsed accordingly Note: the cost of treatment with ranitidine oral liquid is more than 10 times higher than that of ranitidine tablets. Following the derestriction of access PHARMAC will be monitoring expenditure on ranitidine oral liquid more closely and may, subject to consultation and PHARMAC Board approval, restrict access again if expenditure was to grow substantially. URSODEOXYCHOLIC ACID – Special Authority see SA0914 0841 Retail pharmacy Cap 300 mg ......................................................................... 269.98 100 ✔ Actigall ➽ SA0914 0841 Special Authority for Subsidy Initial application only from any relevant practitioner a gastroenterologist or general physician. Approvals valid for 6 months for applications meeting the following criteria: Both: continued...

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

S29

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 July 2008 (continued)

continued... 1. Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and 2. Patient not requiring a liver transplant (bilirubin > 170umol/l; decompensated cirrhosis). Note: Liver biopsy is not usually required for diagnosis but is helpful to stage the disease. Renewal only from any relevant practitioner a gastroenterologist or general physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. Note: Actigall is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 170 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transplant centre. Treatment failure – doubling of serum bilirubin levels, absence of a significant decrease in ALP or ALT and AST, development of varices, ascites or encephalopathy, marked worsening of pruritus or fatigue, histological progression by two stages, or to cirrhosis, need for transplantation. 34 BENZYDAMINE HYDROCHLORIDE – Retail pharmacy-Specialist prescription Soln 0.15% ............................................................................... 9.00 500 ml (15.36) ALFACALCIDOL – Retail pharmacy-Specialist Cap 0.25 µg ........................................................................... 26.32 Cap 1 µg ................................................................................ 87.98 Oral drops 2 µg per ml ........................................................... 60.68 100 100 20 ml OP

Difflam ✔ One-Alpha ✔ One-Alpha ✔ One-Alpha

ALPHA TOCOPHERYL ACETATE – Special Authority see SA0915 0264 – Hospital pharmacy [HP3] Water solubilised soln 156 iu/ml, with calibrated dropper ......... 18.30 50 ml OP ✔ Micelle E ➽ SA0915 0264 Special Authority for Subsidy Initial application only from any relevant practitioner a paediatrician or respiratory specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1. Cystic fibrosis patient; or Both: 2. Infant or child with liver disease or short gut syndrome; and 3. Requires vitamin supplementation. Renewal only from any relevant practitioner a paediatrician or respiratory specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

CALCITRIOL – Retail pharmacy-Specialist ❋ Cap 0.25 µg ........................................................................... 13.45 ❋ Cap 0.5 µg ............................................................................. 24.95 ❋ Oral liq 1 µg per ml ................................................................. 39.40 CALCIUM POLYSTYRENE SULPHONATE – Retail pharmacy-Specialist Powder ................................................................................. 169.85 SODIUM POLYSTYRENE SULPHONATE – Retail pharmacy-Specialist Powder ................................................................................... 89.10 LEVONORGESTREL ❋ Tab 1.5 mg ............................................................................ 12.50 a) Maximum of 1 2 tab per prescription b) Up to 5 tab available on a PSO

100 100 10 ml OP 300 g OP 450 g OP 1

✔ Calcitriol-AFT ✔ Calcitriol-AFT ✔ Rocaltrol solution ✔ Calcium Resonium ✔ Resonium-A

47 47 73

✔ Postinor-1

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 July 2008 (continued)

117 ZIPRASIDONE Ziprasidone is subsidised for patients suffering from schizophrenia or related psychoses after a trial of an effective dose of risperidone or quetiapine that has been discontinued, or is in the process of being discontinued, because of unacceptable side effects or inadequate response, and the prescription is endorsed accordingly.

Effective 1 June 2008

54 LOSARTAN ➽ SA0862 Special Authority for Subsidy Initial application only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Both: 1.1 Patient with congestive heart failure; and 1.2 Either: 1.2.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 1.2.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years; or 2 All of the following: 2.1 Patient with raised blood pressure; and 2.2 Use of fully funded beta blockers or diuretics are contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses; and 2.3 Either: 2.3.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 2.3.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. ➽ SA0911 Special Authority for Subsidy Initial application – (ACE inhibitor intolerant) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patient has persistent ACE inhibitor induced cough that has recurred by ACE inhibitor retrial (same or new ACE inhibitor); or 2 Patient has a history of angioedema. Initial application - (Unsatisfactory response to ACE inhibitor) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient’s condition is not adequately controlled on maximum tolerated dose of an ACE inhibitor. Initial application (patient has had an approval for losartan with hydrochlorothiazide prior to 1 May 2008) from any relevant practitioner. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment. 54 LOSARTAN WITH HYDROCHLOROTHIAZIDE ➽ SA0862 Special Authority for Subsidy Initial application only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Both: 1.1 Patient with congestive heart failure; and 1.2 Either: 1.2.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 1.2.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years; or continued...

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 June 2008 (continued)

continued... 2 All of the following: 2.1 Patient with raised blood pressure; and 2.2 Use of fully funded beta blockers or diuretics are contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses; and 2.3 Either: 2.3.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 2.3.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. ➽ SA0911 Special Authority for Subsidy Initial application – (ACE inhibitor intolerant) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patient has persistent ACE inhibitor induced cough that has recurred by ACE inhibitor retrial (same or new ACE inhibitor); or 2 Patient has a history of angioedema. Initial application - (Unsatisfactory response to ACE inhibitor) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient’s condition is not adequately controlled on maximum tolerated dose of an ACE inhibitor. Initial application (patient has had an approval for losartan with hydrochlorothiazide prior to 1 May 2008) from any relevant practitioner. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment. 109 GABAPENTIN ➽ SA0873 Special Authority for Subsidy Initial application — (Epilepsy - new patients) from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: Either: 1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or 2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents. Note: “Optimal treatment with other antiepilepsy agents” is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient’s age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Initial application — (Epilepsy - patient has had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life from gabapentin, topiramate, vigabatrin and/or lamotrigine. Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient’s perspective. Initial application — (Neuropathic pain - new patients) from any relevant practitioner. Approvals valid for 3 months where the patient has tried and failed, or has been unable to tolerate, treatment with a tricyclic antidepressant AND an anticonvulsant agent. Initial application — (Neuropathic pain - patient has had an approval for gabapentin for neuropathic pain prior to 1 August 2007) from any relevant practitioner. Approvals valid for 2 years where the patient has demonstrated a marked improvement in their control of pain (prescriber determined). Renewal — (Epilepsy) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life. Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient’s perspective. continued...

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 June 2008 (continued)

continued... If the patient had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Renewal — (Neuropathic pain) from any relevant practitioner. Approvals valid for 2 years where the patient has demonstrated a marked improvement in their control of pain (prescriber determined). Note: If the patient had an approval for gabapentin for neuropathic pain prior to 1 August 2007 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. 110 TOPIRAMATE ➽ SA0874 Special Authority for Subsidy Initial application — (new patients) from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: Both: 1 Patient has epilepsy; and 2 Either: 2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or 2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents. Note: “Optimal treatment with other antiepilepsy agents” is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient’s age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Initial application — (patient has had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life life from gabapentin, topiramate, vigabatrin and/or lamotrigine. Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient’s perspective. Renewal from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life. Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient’s perspective. If the patient had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. 111 VIGABATRIN ➽ SA0875 Special Authority for Subsidy Initial application — (new patients) from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: All of the following: 1 Patient has epilepsy; and 2 Either: 2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or 2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; and 3 Either: 3.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter); or 3.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient’s visual fields. Notes: “Optimal treatment with other antiepilepsy agents” is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient’s age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance. continued...

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 June 2008 (continued)

continued... Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages. Initial application — (patient has had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life from gabapentin, topiramate, vigabatrin and/or lamotrigine; and 2 Either: 2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for the duration of treatment with vigabatrin; or 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient’s visual fields. Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient’s perspective. Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages. Renewal from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 The patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life; and 2 Either: 2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for duration of treatment with vigabatrin; or 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient’s visual fields. Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient’s perspective. Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages. If the patient had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. 164 CARBOHYDRATE ➽ SA0579 SA0912 Special Authority for Subsidy Initial application - (Cystic fibrosis or renal failure) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Either: 1 cystic fibrosis; or 2 chronic renal failure or continuous ambulatory peritoneal dialysis (CAPD) patient. Initial application - (Indications other than cystic fibrosis or renal failure) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: 1 cancer in children; or 2 cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or 3 failure to thrive; or 4 growth deficiency; or 5 bronchopulmonary dysplasia; or 6 premature and post premature infant; or 7 inborn errors of metabolism continued... ❋ Three months or six months, as applicable, dispensed all-at-once

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 June 2008 (continued)

continued... Renewal - (Cystic fibrosis or renal failure) only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted. Renewal - (Indications other than cystic fibrosis or renal failure) only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.

Effective 1 May 2008

91 PYRAZINAMIDE – Retail pharmacy-Specialist No patient co-payment payable ❋ Tab 500 mg ........................................................................... 59.00 100 ✔ AFT-Pyrazinamide

S29

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price

Effective 1 July 2008

27 OMEPRAZOLE ( subsidy) ❋ Cap 10 mg ................................................................................ 2.14 (5.95) ❋ Cap 20 mg ................................................................................ 3.05 (5.95) ❋ Cap 40 mg ................................................................................ 3.59 (8.84) GLICLAZIDE ( subsidy) ❋ Tab 80 mg .............................................................................. 22.24 30 Omezol 30 Omezol 30 Omezol 500

29 32 35 62

✔ Apo-Gliclazide

URSODEOXYCHOLIC ACID – Special Authority see SA0841 – Retail Pharmacy ( subsidy) Cap 300 mg .......................................................................... 179.00 100 ✔ Actigall TRIAMCINOLONE ACETONIDE ( subsidy) 0.1% in Dental Paste USP .......................................................... 4.38 CLOTRIMAZOLE ( subsidy) ❋ Crm 1% ..................................................................................... 0.50 a) Only on a prescription b) Not in combination MICONAZOLE NITRATE ( subsidy) ❋ Crm 2% ..................................................................................... 0.42 a) Only on a prescription b) Not in combination BETAMETHASONE VALERATE ( subsidy) ❋ Crm 0.1% ................................................................................. 2.00 ❋ Oint 0.1% ................................................................................. 2.20 HYDROCORTISONE ( price) ❋ Crm 1% – Only on a prescription ............................................ 12.20 EMULSIFYING OINTMENT ( subsidy) ❋ Ointment BP .............................................................................. 3.69 5 g OP 20 g OP

✔ Oracort

✔ Clomazol

15 g OP

✔ Multichem

50 g OP 50 g OP 500 g

✔ Beta Cream ✔ Beta Ointment

✔ PSM

65 68

500 g

✔ AFT

SALICYLIC ACID ( subsidy) Powder – Only in combination ................................................. 15.00 500 g (55.63) David Craig 1) Only in combination with a dermatological base or proprietary Topical Corticosteroid – Plain or collodion flexible, 2) With or without other dermatological galenicals 3) Maximum 20 g or 20 ml per prescription when prescribed with white soft paraffin or collodion flexible. SULPHUR ( subsidy) Precipitated – Only in combination ............................................. 6.50 100 g (9.25) PSM 1) Only in combination with a dermatological base or proprietary Topical Corticosteroid – Plain, 2) With or without other dermatological galenicals. Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber. ❋ Three months or six months, as applicable, dispensed all-at-once

▲

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price - effective 1 July 2008 (continued)

69 SUNSCREENS, PROPRIETARY – Subsidy by endorsement ( subsidy) Only if prescribed for a patient with severe phostosensitivity secondary to a defined clinical condition and the prescription is endorsed accordingly Crm........................................................................................... 2.55 100 g OP (5.89) Hamilton Sunscreen 1.28 50 g OP (5.53) Aquasun Oil Free Faces SPF 30+ Lotn .......................................................................................... 3.19 125 ml OP (8.82) Aquasun Sensitive SPF 30+ 125 ml OP (9.38) Aquasun 30+ CONDOMS ( subsidy) ❋ 52mm – Up to 144 dev available on a PSO .............................. 13.36 ❋ 52 mm extra strength – Up to 144 dev available on a PSO........ 13.36 ❋ 54 mm, shaped – Up to 144 dev available on a PSO .................. 1.11 (2.60) ❋ 54 mm, shaped – Up to 144 dev available on a PSO ................ 13.36 (14.84) ❋ 56mm, shaped – Up to 144 dev available on a PSO ................... 1.11 (1.24) ❋ 56mm, shaped – Up to 144 dev available on a PSO ................. 13.36 (14.84) 144 144 12 144 Lifestyles Flared 12 Durex Confidence 144 Durex Confidence ✔ Marquis Supalite ✔ Marquis Protecta Lifestyles Flared

PAMIDRONATE DISODIUM – Special Authority see SA0091 – Hospital Pharmacy [HP3] ( subsidy) Inj 3 mg per ml, 5 ml ............................................................... 18.75 1 ✔ Pamisol Inj 3 mg per ml,10 ml .............................................................. 37.50 1 ✔ Pamisol Inj 6 mg per ml,10 ml .............................................................. 75.00 1 ✔ Pamisol DESMOPRESSIN ( subsidy) ▲ Nasal Spray 10 µ per dose – Retail Pharmacy – Specialist ................................................ 29.94

6 ml OP

✔ Desmopressin-PH&T

CEFUROXIME AXETIL – Subsidy by endorsement ( subsidy) Only if prescribed for prophylaxis of endocarditis and the prescription is endorsed accordingly. Tab 250 mg ............................................................................ 29.40 50 ✔ Zinnat FLUCONAZOLE - Hospital Pharmacy [HP3]- Specialist ( subsidy) Cap 50 mg ................................................................................ 6.82 Cap 150 mg .............................................................................. 1.30 Cap 200 mg ............................................................................ 19.05 TERBINAFINE ( subsidy) Tab 250 mg ............................................................................ 25.50 NORFLOXACIN ( subsidy) Tabs 400 mg – Maximum of 6 tab per prescription; can be waived by endorsement – Retail Pharmacy – Specialist ................................................ 22.50 28 1 28 100 ✔ Pacific ✔ Pacific ✔ Pacific

90 96

✔ Apo-Terbinafine

100

✔ Arrow-Norfloxacin

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price - effective 1 July 2008 (continued)

113 115 METOCLOPRAMIDE HYDROCHLORIDE ( subsidy) ❋ Inj 5 mg per ml, 2 ml – Up to 5 inj available on a PSO ............ 4.50 PERGOLIDE – Retail Pharmacy – Specialist ( subsidy) ▲ Tab 0.25 mg ........................................................................... 48.00 ▲ Tab 1 mg .............................................................................. 170.00 CALCIUM FOLINATE ( subsidy) Inj 50 mg – PCT – Hospital pharmacy [HP1] – Specialist ......... 24.50 PENTOSTATIN (DEOXYCOFORMYCIN) – PCT only – Specialist (Now CBS) Inj 10 mg ............................................................................. CBS SALBUTAMOL WITH IPRATROPIUM BROMIDE ( subsidy) Aerosol inhaler, 100 µg with ipratropium bromide, 20 µg per dose ................................................................... 13.50 BRIMONIDINE TARTARATE ( subsidy) ❋ Eye Drops 0.2%......................................................................... 7.93 GLYCEROL ( subsidy) ❋ Liquid – Only in combination.................................................... 19.80 (24.75) Only in extemporaneously compounded oral liquid preparations METHYL HYDROXYBENZOATE ( subsidy) Powder ................................................................................... 10.00 (18.45) METHYLCELLULOSE ( subsidy) Powder ................................................................................... 14.00 (17.72) SODIUM BICARBONATE ( subsidy) Powder BP - Only in combination............................................... 9.80 (11.99) (29.50) Only in extemporaneously compounded omeprazole suspension 5 100 100 5 ✔ Pfizer

✔ Permax ✔ Permax ✔ Calcium Folinate Ebewe ✔ Nipent S29

126

131 148

200 dose OP ✔ Combivent 5 ml OP 2000 ml Midwest

153 161

✔ AFT

161

25 g PSM 100 g MidWest 500 g Biomed David Craig

161

162

178

AMINOACID FORMULA WITHOUT METHIONINE – Special Authority see SA0732 – Hospital pharmacy [HP3] ( subsidy) Powder ................................................................................. 461.94 500 g OP

✔ XMET Maxamum

178

AMINOACID FORMULA WITHOUT VALINE, LEUCINE AND ISOLEUCINE – Special Authority see SA0732 – Hospital pharmacy [HP3] ( subsidy) Powder ................................................................................. 300.54 500 g OP ✔ MSUD Maxamaid 437.22 ✔ MSUD Maxamum

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price - effective 1 July 2008 (continued)

179 AMINOACID FORMULA WITH MINERALS WITHOUT PHENYLALANINE – Special Authority see SA0733 – Hospital pharmacy [HP3] ( subsidy) Powder ................................................................................... 58.44 250 g OP ✔ Metabolic Mineral Mixture

Effective 1 June 2008

54 LOSARTAN – Special Authority see SA0911 ( subsidy) ❋ Tab 12.5 mg ........................................................................... 17.40 ❋ Tab 50 mg ............................................................................. 23.10 30 30 ✔ Cozaar ✔ Cozaar

54 66 86

LOSARTAN WITH HYDROCHLOROTHIAZIDE – Special Authority see SA0911 ( subsidy) Tab 50 mg with hydrochlorothiazide 12.5 mg........................... 30.00 30 ✔ Hyzaar PARAFFIN ( subsidy) White soft – Only in combination ............................................. 20.20 CEFUROXIME SODIUM – Hospital Pharmacy [HP3] ( subsidy) Inj 750 mg - Maximum of 1 inj per prescription; can be waived by endorsement ............................................ 10.71 Inj 1.5 g - Hospital pharmacy [HP3] – Specialist – Subsidy by endorsement ....................................................... 4.04 ASPIRIN ( subsidy) ❋ Tab dispersible 300 mg – Up to 30 tab available on a PSO ....... 21.50 (22.50) MORPHINE SULPHATE ( subsidy) a) Only on a controlled drug form b) No patient co-payment payable Inj 10 mg per ml, 1 ml – Up to 5 inj available on a PSO .............. 4.50 Inj 30 mg per ml, 1 ml – Up to 5 inj available on a PSO .............. 4.98 2,500 g

✔ IPW

5 1 1000

✔ Zinacef ✔ Zinacef

103

Ethics Aspirin

105

5 5

✔ Mayne ✔ Mayne

147

SALBUTAMOL ( subsidy) Aerosol inhaler, 100 µg per dose CFC free – Up to 1000 dose available on a PSO........................................................ 3.80 200 dose OP ✔ Salamol (6.00) Ventolin ACETIC ACID WITH 1, 2- PROPANEDIOL DIACETATE AND BENZETHONIUM ( subsidy) Ear drops 2% with 1, 2-Propanediol diacetate 3% and benzethonium chloride 0.02 % .............................................. 6.97 35 ml OP ✔ Vosol CARBOHYDRATE AND FAT SUPPLEMENT – Special Authority see SA0581 – Hospital pharmacy [HP3] ( subsidy) Powder (neutral) ..................................................................... 60.31 400 g OP

151

164

✔ Duocal Super Soluble Powder

166

FAT SUPPLEMENT – Special Authority see SA0899 – Hospital pharmacy [HP3] ( subsidy) Oil ........................................................................................... 28.73 250 ml OP ✔ Liquigen 30.00 500 ml OP ✔ MCT oil (Nutricia)

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price - effective 1 June 2008 (continued)

168 169 169 171 FAT MODIFIED FEED – Special Authority see SA0615– Hospital pharmacy [HP3] ( subsidy) Powder ................................................................................... 60.48 400 g OP ✔ Monogen ENTERAL/ORAL FEED 1KCAL/ML – Special Authority see SA0607– Hospital pharmacy [HP3] ( subsidy) Powder ................................................................................... 78.97 400 g OP ✔ Generaid Plus ENTERAL/ORAL FEED 1KCAL/ML – Special Authority see SA0606 – Hospital pharmacy [HP3] ( subsidy) Liquid ...................................................................................... 54.00 400 g OP ✔ Kindergen ORAL ELEMENTAL FEED 0.8KCAL/ML – Special Authority see SA0592 – Hospital pharmacy [HP3] ( subsidy) Liquid (grapefruit) ..................................................................... 9.50 250 ml OP ✔ Elemental 028 Extra Liquid (pineapple & orange) ...................................................... 9.50 250 ml OP ✔ Elemental 028 Extra Liquid (summer fruit) ................................................................ 9.50 250 ml OP ✔ Elemental 028 Extra MULTIVITAMINS – Special Authority see SA0600– Hospital pharmacy [HP3] ( subsidy) Powder ................................................................................... 36.00 100 g OP ✔ Paediatric Seravit LOW CALCIUM INFANT FORMULA – Special Authority see SA0601– Hospital pharmacy [HP3] ( subsidy) Powder ................................................................................... 44.40 400 g OP ✔ Locasol

179 180

Effective 1 May 2008

27 OMEPRAZOLE ( subsidy) ❋ Cap 10 mg ................................................................................ 2.00 ❋ Cap 20 mg ................................................................................ 2.85 ❋ Cap 40 mg ................................................................................ 3.35 46 60 DEXTROSE ( subsidy) ❋ Inj 50%, 10 ml – Up to 5 inj available on a PSO ........................ 22.75 GLYCERYL TRINITRATE ( subsidy) ❋ TDDS 5 mg ............................................................................. 16.56 ❋ TDDS 10 mg ........................................................................... 19.60 POVIDONE IODINE ( price) Skin preparation, povidone iodine 10% with 70% alcohol ............ 8.13 (18.63) 1.63 (6.04) SUNSCREENS, PROPRIETARY – Sunscreens by endorsement ( price) Crm........................................................................................... 1.74 (5.84) 28 28 28 ✔ Dr Reddy’s Omeprazole ✔ Dr Reddy’s Omeprazole ✔ Dr Reddy’s Omeprazole ✔ Biomed ✔ Nitroderm TTS ✔ Nitroderm TTS

5 30 30 500 ml

Orion 100 ml Orion 50 g OP Aquasun Oil Free Faces SPF 30+

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price - effective 1 May 2008 (continued)

80 OESTRADIOL ( subsidy) ❋ Tab 2 mg .................................................................................. 4.12 (7.00) 28 OP Estrofem ✔ AFT-Leflunomide ✔ AFT-Leflunomide

LEFLUNOMIDE – Special Authority see SA0635 – Retail Pharmacy ( subsidy) Tab 10 mg .............................................................................. 55.00 30 Tab 20 mg .............................................................................. 76.00 30

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to General Rules

Effective 1 June 2008

12 “Close Control” means the dispensing of a Community Pharmaceutical, in accordance with a Prescription, in quantities less than one 90 Day Lot (or, in the case of for oral contraceptives, less than one 180 Day Lot) for a Community Pharmaceutical referred to in Section F Part I, or in quantities less than a Monthly Lot for any other Community Pharmaceutical, where any of a), b) or c) apply. as applicable, where a) All of the following conditions are met: i) the Community Pharmaceutical is a tri-cyclic antidepressant, antipsychotic, benzodiazepine, a Class B Controlled Drug, or any other Community Pharmaceutical that has been prescribed for a patient who: 1A) is not a resident in a Penal Institution, Rest Home or Residential Disability Care Institution; and 2B) either of the following: i) in the opinion of the prescribing Practitioner Doctor, Midwife or Nurse Prescriber is: a. frail; or b. infirm; or c. unable to manage their medication without additional support; or d. intellectually impaired; or and e. requires close monitoring due to recent initiation onto, or dose change for, the Community Pharmaceutical (applicable to the patient’s first changed Prescription only); and f. requires that Community Pharmaceutical to be dispensed in a smaller quantity than that for which it is currently funded, or ii) the Community Pharmaceutical is any of the following: a. a tri-cyclic antidepressant; or b. an antipsychotic; or c. a benzodiazepine; or d. a Class B Controlled Drug; and ii) the prescribing Practitioner Doctor, Midwife or Nurse Prescriber has: A) endorsed each Community Pharmaceutical on the Prescription clearly with the words “close control” or “CC”; and B) initialled the endorsement in their the prescribers own handwriting; and C)specified the maximum quantity or period of supply to be dispensed at any one time. b) All of the following conditions are met: i) The Community Pharmaceutical is prescribed for a patient who is a resident in a Rest Home or Residential Disability Care Institution; and A)the quantity or period of supply to be dispensed at any one time is not less than 28 days’ supply; and B)the prescriber or pharmacist has written the name of the Rest Home or Residential Disability Care Institution on the prescription; and C)the prescriber or pharmacist has: 1) written on the Prescription the words “close control” or “CC” (this applies to all medicines prescribed on the prescription), and 2) initialled the endorsement/annotation in their own handwriting; and 3) specified the maximum quantity or period of supply to be dispensed at any one time. c) All of the following conditions are met: i) where PHARMAC has approved and notified pharmacists to annotate prescriptions for a specified Community Pharmaceutical(s) “Close Control” without prescriber endorsement for a specified time; and ii) the dispensing pharmacist has: A)clearly annotated each of the approved Community Pharmaceuticals that appear on the prescription with the words “close control” or “CC”; and B)initialled the annotation in their own handwriting; and C)specified the maximum quantity or period of supply to be dispensed at any one time, as specified by PHARMAC at the time of notification. Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber. ❋ Three months or six months, as applicable, dispensed all-at-once

▲

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to PSO

Effective 1 July 2008

GLYCERYL TRINITRATE Tab 600 µg ....................................100 HYDROXOCOBALAMIN Inj 1 mg per ml, 1 ml ......................6

Effective 1 June 2008

CONDOMS 53 mm extra strength .....................144 55 mm ...........................................144 LEVONORGESTREL Tab 1.5 mg.....................................5

Effective 1 May 2008

CONDOMS 53 mm (chocolate) .........................144 55 mm (strawberry) .......................144

Changes to Sole Subsidised Supply

Effective 1 July 2008

There are no new Sole Subsidised Supply products effective 1 July 2008.

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items

Effective 1 July 2008

28 31 INSULIN ISOPHANE ▲ Inj animal (pork) 100 u per ml ................................................. 25.26 10 ml OP ✔ Protaphane

GLUCOSE BLOOD DIAGNOSTIC TEST METER – Subsidy by endorsement a) Maximum of 1 meter per prescription b) A diagnostic blood glucose test meter is subsidised for patients who begin insulin or sulphonylurea therapy after 1 March 2005. Only one meter per patient. No further prescriptions will be subsidised. The prescription must be endorsed accordingly. Meter ...................................................................................... 19.00 1 ✔ Accu-Chek Advantage GLUCOSE DEHYDROGENASE The number of test strips available on a prescription is restricted to 50 unless: 1) Prescribed with insulin or a sulphonylurea but are on a different prescription and the prescription is endorsed accordingly; or 2) Prescribed on the same prescription as insulin or a sulphonylurea in which case the prescription is deemed to be endorsed; or 3) Prescribed for a pregnant woman with diabetes and endorsed accordingly. Blood/glucose test strips ........................................................ 22.00 50 test OP ✔ Accu-Chek Advantage MUCILAGINOUS LAXATIVES WITH STIMULANTS ❋ Dry ........................................................................................... 4.40 (12.00) METHOXSALEN – Retail pharmacy-Specialist Cap 10 mg .............................................................................. 11.66 VALACICLOVIR Tab 500 mg .......................................................................... 163.80 NELFINAVIR – Special Authority see SA0779 – Hospital pharmacy [HP1] Tab 250 mg ......................................................................... 600.00 Powder 50 mg per g ............................................................... 55.44 MORPHINE SULPHATE a) Only on a controlled drug form b) No patient co-payment payable Suppos 10 mg......................................................................... 11.08 Suppos 20 mg......................................................................... 20.31 TRIFLUOPERAZINE HYDROCHLORIDE ‡ Oral liq 1 mg per ml ................................................................ 74.80 250 g OP Granocol 25 30 270 144 g OP ✔ Oxsoralen ✔ Valtrex ✔ Viracept ✔ Viracept

67 91 95

105

12 12 1,000 ml

✔ Martindale S29 ✔ Martindale S29 ✔ Stelazine

117 147

BUDESONIDE WITH EFORMOTEROL – Special Authority see SA0838– Retail pharmacy Aerosol inhaler 100 µg with eformoterol fumarate 6 µg ............ 55.00 120 dose OP ✔ Symbicort Rapihaler Aerosol inhaler 200 µg with eformoterol fumarate 6 µg ............ 60.00 120 dose OP ✔ Symbicort Rapihaler TERBUTALINE SULPHATE Inj 500 µg per ml, 1 ml ........................................................... 10.21 5 ✔ Bricanyl

147

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items - effective 1 June 2008

27 PANTOPRAZOLE ❋ Tab 20 mg ............................................................................... 2.24 (22.00) ❋ Tab 40 mg ............................................................................... 3.36 (28.00) ECONAZOLE NITRATE Crm 1% ..................................................................................... 1.00 (1.30) 28 Somac 28 Somac 15 g OP Ecreme

87 87 131

CLARITHROMYCIN – Maximum of 500 mg per prescription; can be waived by Special Authority see SA0657 Tab 250 mg ............................................................................. 7.75 14 ✔ Clarac ERYTHROMYCIN LACTOBIONATE Inj 1 g ....................................................................................... 6.50 MITOZANTRONE – PCT only – Specialist Inj 2 mg per ml, 10ml ........................................................... 330.00 1 1 ✔ ERA ✔ Onkotrone

Effective 1 May 2008

47 WATER 1) On a prescription or Practitioner’s Supply Order only when on the same form as an injection listed in the Pharmaceutical Schedule requiring a solvent or diluent; or 2) On a bulk supply order; or 3) When used in the extemporaneous compounding of eye drops. Purified for inj 5 ml – Available on a PSO ................................... 9.31 50 ✔ AstraZeneca Purified for inj 10 ml – Available on a PSO ............................... 10.38 50 ✔ AstraZeneca RITONAVIR – Special Authority see SA0779 – Hospital pharmacy [HP1] Oral liq 80 mg per ml ............................................................ 277.28 Note: The 90 ml OP of Norvir will continue to be listed fully subsidised. NAPROXEN SODIUM ❋ Tab 275 mg ............................................................................. 5.00 ALPRAZOLAM – Retail pharmacy-Specialist Month Restriction Tab 250 µg .............................................................................. 4.77 (8.11) ‡ Safety cap for extemporaneously compounded oral liquid preparations. Tab 500 µg .............................................................................. 8.60 (16.26) ‡ Safety cap for extemporaneously compounded oral liquid preparations. Tab 1 mg ............................................................................... 15.70 (32.51) ‡ Safety cap for extemporaneously compounded oral liquid preparations. SULPHACETAMIDE SODIUM ❋ Eye drops 10% ......................................................................... 3.60 240 ml OP ✔ Norvir

99 119

100

✔ Synflex

100 Xanax 100 Xanax 100 Xanax

152

15 ml OP

✔ Acetopt

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items - effective 1 May 2008 (continued)

161 ACETYLCYSTEINE – Hospital pharmacy [HP1]-Specialist Inj 200 mg per ml, 10 ml ...................................................... 137.06 (242.50) 10 Parvolex

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted

Effective 1 August 2008

52 PRAZOSIN HYDROCHLORIDE ❋ Tab 1 mg .................................................................................. 2.99 ❋ Tab 2 mg ................................................................................. 4.00 ❋ Tab 5 mg ................................................................................. 6.50 100 100 100 ✔ Hyprosin ✔ Hyprosin ✔ Hyprosin

Effective 1 September 2008

103 ASPIRIN ❋ Tab dispersible 300 mg – Up to 30 tab available on a PSO ....... 21.50 (22.50) 1000 Ethics Aspirin

Effective 1 November 2008

58 95 VERAPAMIL HYDROCHLORIDE ❋ Tab 80 mg ............................................................................... 6.00 100 ✔ Verpamil ✔ Norvir

RITONAVIR – Special Authority see SA0779 on page 93 – Hospital pharmacy [HP1] Cap 100 mg .......................................................................... 242.55 168 Note – the 84 pack size will continue to be listed fully subsidised

Effective 1 December 2008

30 73 TOLBUTAMIDE ❋ Tab 500 mg ............................................................................ 12.00 LEVONORGESTREL ❋ Tab 750 µg .............................................................................. 8.50 a) Maximum of 4 tab per prescription b Up to 10 tab available on a PSO CYPROTERONE ACETATE – Hospital pharmacy [HP3] – Specialist Inj 100 mg per ml, 3 ml ......................................................... 196.82 OESTRADIOL VALERATE ❋ Tab 1 mg .................................................................................. 4.12 ORPHENADRINE CITRATE Inj 30 mg per ml, 2 ml ............................................................... 9.60 (20.50) PROCHLORPERAZINE ❋ Suppos 5 mg............................................................................. 9.52 (18.13) 100 2 ✔ Diatol ✔ Postinor-2

78 79 102

3 28 3

✔ Androcur Depot ✔ Progynova

Norflex 5 Stemetil

114

168

DIABETIC ENTERAL FEED 1KCAL/ML – Special Authority see SA0594 – Hospital Pharmacy [HP3] Liquid ........................................................................................ 7.50 1,000 ml OP ✔ Glucerna RTH

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted - effective 1 December 2008 (continued)

168 ORAL FEED 1KCAL / ML Liquid (vanilla)........................................................................... 1.88 250 ml OP ✔ Glucerna Note : Glucerna RTH and Glucerna replaced by Glucerna Select RTH and Glucerna See New Listings

Effective 1 January 2009

63 DIFLUCORTOLONE VALERATE Oint 0.1% .................................................................................. 8.97 (15.23) SALICYLIC ACID Powder – Only in combination ................................................. 15.00 (55.63) TENOXICAM ❋ Suppos 20 mg .......................................................................... 5.30 50 g OP Nerisone 500 g David Craig 10 ✔ Tilcotil

99 173

ENTERAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority see SA0702 – Hospital pharmacy [HP3] Liquid ........................................................................................ 3.50 500 ml OP ✔ Nutrison Energy Multi Fibre GLUTEN FREE PASTA – Special Authority see SA0722– Hospital pharmacy [HP3] Garlic and Parsley Spirals .......................................................... 2.00 250 g OP (2.63)

177

Orgran

179

AMINOACID FORMULA WITH MINERALS WITHOUT PHENYLALANINE – Special Authority see SA0733 – Hospital pharmacy [HP3] Powder ................................................................................... 45.06 250 g OP ✔ Aminogran Mineral Mix

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes to Part II

Effective 1 July 2008

ALLOPURINOL (expiry of HSS) Tab 100 mg....................................Progout Tab 300 mg....................................Progout 11.45 21.20 500 500 1% 1% Dec-05 Dec-05 Allohexal Allorin Zyloprim Allohexal Allorin Zyloprim (B) (B) (B) (B) (B) (B) Orion AFT (B) Mayne Alphagan

AMITRIPTYLINE (expiry of HSS) Tab 10 mg......................................Amitrip Tab 25 mg......................................Amitrip Tab 50 mg......................................Amitrip AMOXYCILLIN (expiry of HSS) Inj 250 mg......................................Ibiamox Inj 500 mg......................................Ibiamox Inj 1 g.............................................Ibiamox AQUEOUS (expiry of HSS) Cream ............................................Multichem Cream ............................................Multichem BEZAFIBRATE (expiry of HSS) Tab 200 mg....................................Fibalip BLEOMYCIN SULPHATE (expiry of HSS) Inj 15,000 iu ...................................Blenoxane BRIMONIDINE TARTARATE (new listing) Eye drops 0.2% ..............................AFT

3.00 3.40 5.20 6.32 7.32 11.00 1.86 2.37 8.80 680.00 7.93

100 100 100 5 5 5 100 g 500 g 90 10 5 ml

1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1%

Dec-05 Dec-05 Dec-05 July-06 July-06 July-06 Nov-05 Nov-05 Dec-05 Sept-05 Sept-08

BUPIVICAINE HYDROCHLORIDE WITH FENTANYL (expiry of HSS) Inj 0.125% with 2µg fentanyl per ml, 15 ml prefilled syringe ................Biomed 5.95 Inj 0.125% with 2µg fentanyl per ml, 20 ml prefilled syringe ................Biomed 7.45 Inf 0.125% with 2µg fentanyl per ml, 100 ml bag ................................Bupafen 17.50 Inf 0.125% with 2µg fentanyl per ml, 200 ml bag ................................Bupafen 18.50 CALCIUM (new listing) Tab eff 1 g......................................Calsource 6.54

1 1 1 1 30

1% 1% 1% 1% 1%

Sept-05 Sept-05 Sept-05 Sept-05 Sept-08

(B) (B) Marcain Marcain Calci-Tab Effervescent

Calcium Sandoz 6.54 30 Note – Calcium Sandoz tab eff 1 g to be delisted 1 September 2008.

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes - effective 1 July 2008 (continued)

CALCIUM FOLINATE ( price and addition of HSS) Inj 50 mg........................................Calcium Folinate 24.50 Ebewe Inj 100 mg......................................Calcium Folinate 9.75 Ebewe Inj 300 mg .....................................Calcium Folinate 30.00 Ebewe Inj 1 g ............................................Calcium Folinate 100.00 Ebewe CEFAZOLIN SODIUM (expiry of HSS) Inj 50mg.........................................m-Cefazolin Inj 1 g.............................................m-Cefazolin CEFEPIME HYDROCHLORIDE (expiry of HSS) Inj 1 g, 15 ml ..................................Maxipime Inj 2 g, 77 ml ..................................Maxipime CEFOTAXIME SODIUM (expiry of HSS) Inj 500 mg vial................................AFT Inj 1 g vial ......................................AFT 13.60 18.60 23.00 46.00 3.25 3.94 5 1 1 1 1% 1% 1% 1% Sept-08 Sept-08 Sept-08 Sept-08 Leucovorin Calcium Hospira (B) Leucovorin Calcium Hospira (B)

10 10 1 1 1 1

1% 1% 1% 1% 1% 1%

Sept-06 Sept-06 Sept-05 Sept-05 Oct-05 Oct-05

Biochemie Novartis (B) (B) (B) Aventis Mayne Aventis Mayne Novartis Novartis Novartis Hospira Novartis Ceftazidime 2GM Hospira

CEFTAZIDIME ( price and addition of HSS) Inj 500 mg......................................Fortum Inj 1 g.............................................Fortum Inj 2 g.............................................Fortum

2.84 5.63 11.25

1 1 1

1% 1% 1%

Sept-08 Sept-08 Sept-08

Note – Hospira ( Mayne ) brand of ceftazidime inj 2 g to be delisted from 1 September 2008. CEFTRIAXONE SODIUM (expiry of HSS) Inj 500 mg......................................AFT Inj 1 g.............................................AFT Inj 2 g.............................................AFT CETIRIZINE HYDROCHLORIDE (expiry of HSS) Oral liq 1 mg per ml ........................Allerid C CIPROFLOXACIN (expiry of HSS) Tab 250 mg....................................Cipflox Tab 500 mg....................................Cipflox Tab 750 mg....................................Cipflox 3.99 5.40 10.50 2.75 5.10 8.31 19.30 1 1 1 100 ml 28 28 28 1% 1% 1% 1% 1% 1% 1% Oct-06 Oct-06 Oct-06 Apr-06 Sept-05 Sept-05 Sept-05 Rocephin Rocephin Rocephin (B) Ciproxin Ciproxin Ciproxin

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes - effective 1 July 2008 (continued)

CLINDAMYCIN (expiry of HSS) Inj phosphate 150 mg per ml, 4 ml ...............................Dalacin C CLONIDINE (expiry of HSS) Inj 150 µg per ml, 1 ml ...................Catapres Tab 150 µg ....................................Catapres TDDS 2.5 mg, 100 µg per day ........Catapres-TTS-1 TDDS 5 mg, 200 µg per day ...........Catapres-TTS-2 TDDS 7.5 mg, 300 µg per day ........Catapres-TTS-3 CLOTRIMAZOLE (new listing) Crm1% ...........................................Clomazol

19.45 14.00 30.33 21.29 30.79 39.10 0.50

1 5 100 4 4 4 20 g

1% 1% 1% 1% 1% 1% 1%

Sept-05 Dec-05 Dec-05 Dec-05 Dec-05 Dec-05 Sept-08

(B) (B) (B) (B) (B) (B) Canesten Clocreme Clotrimaderm 1% Fungizid (B) (B) Minirin

CYCLIZINE LACTATE (expiry of HSS) Inj 50 mg per ml, 1 ml ....................Valoid (AFT) CYCLOSPORIN (expiry of HSS) Inf 50 mg per ml, 5 ml ....................Sandimmun DESMOPRESSIN (new listing) Nasal spray 10 µg per dose ............Desmopressin PH&T DESMOPRESSIN (expiry of HSS) Tab 100 µg ...................................Minirin DICLOFENAC SODIUM (addition of HSS) Eye drops 1 mg per ml ...................Voltaren Optha Inj 25 mg per ml, 3 ml (new listing) Voltaren Suppos 12.5 mg.............................Voltaren Suppos 25 mg................................Voltaren Suppos 50 mg................................Voltaren Suppos 100 mg..............................Voltaren DIPYRIDAMOLE (expiry of HSS) Tab long-acting 150 mg..................Pytazen SR EMULSIFYING OINTMENT (new listing) Ointment BP ...................................AFT

14.95 276.30 29.94

5 10 6 ml

1% 1% 1%

Dec-05 Oct-06 Sept-08

36.40 13.80 12.00 1.85 2.22 3.84 6.36 11.52 3.69

30 5 ml 5 10 10 10 10 60 500 g

1% 1% 1% 1% 1% 1% 1% 1% 1%

Sept-05 Sept-08 Sept-08 Sept-08 Sept-08 Sept-08 Sept-08 Oct-05 Sept-08

(B) (B) (B) (B) (B) (B) (B) Persantin IPW Sigma

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes - effective 1 July 2008 (continued)

FLUCLOXACILLIN SODIUM (expiry of HSS) Inj 250 mg......................................Flucloxin Inj 500 mg......................................Flucloxin Inj 1 g ............................................Flucoxin FLUCONAZOLE (new listing) Cap 50 mg .....................................Pacific 4.50 5.30 7.24 5 5 5 1% 1% 1% Oct-05 Oct-05 Oct-05 Floxapen Mayne Floxapen Mayne Floxapen Mayne Flucoran m-Fluconazole Diflucan Rex Canesten Fluconazole Flucoran Diflucan One m-Fluconazole Diflucan Rex Flucoran m-Fluconazole Diflucan Rex (B) (B) (B) (B) (B) (B) (B) Glizon (B) (B) (B)

6.82

Sept-08

Cap 150 mg ..................................Pacific

1.30

Sept-08

Cap 200 mg ...................................Pacific

19.05

Sept-08

FLUDARABINE (expiry of HSS) Tab 10 mg......................................Fludara FLUDARABINE PHOSPHATE (expiry of HSS) Inj 50 mg........................................Fludara FLUPHENAZINE DECANOATE (expiry of HSS) Inj 12.5 mg per 0.5 ml, 0.5 ml ........Modecate Inj 25 mg per ml, 1 ml ....................Modecate Inj 100 mg per ml, 1 ml ..................Modecate GELATIN PLASMA REPLACER (expiry of HSS) Inf 3 5 %, 500 ml bag .....................Haemacel Inf 4%, per 500 ml nag ...................Gelofusine GLICLAZIDE (new listing) Tab 80 mg......................................Apo-Gliclazide GLIPIZIDE (new listing) Tab 5 mg........................................Minidiab GLYCERYL TRINITRATE (addition of HSS) Tab 600 µg (new listing) ................Lycinate Aerosol spray 400 µg per dose .......Nitrolingual Pumpspray

637.50 1,496.25 17.60 27.90 154.50 9.75 108.00 22.24 3.50 8.00 5.16

15 5 5 5 5 1 10 500 100

1% 1% 1% 1% 1% 1% 1% 1% 1%

Sept-05 Sept-05 Oct-05 Oct-05 Oct-05 Oct-05 Nov-05 Sept-08 Sept-08 Sept-08 Sept-08

100 1% 250 dose 1%

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes - effective 1 July 2008 (continued)

HALOPERIDOL (expiry of HSS) Tab 500 µg ....................................Serenace Tab 1.5 mg.....................................Serenace Tab 5 mg........................................Serenace Oral liq 2 mg per ml ........................Serenace HALOPERIDOL DECANOATE (expiry of HSS) Inj 50 mg per ml, 1 ml ....................Haldol Inj 100 mg per ml, 1 ml ..................Haldol Concentrate HYDROCORTISONE (new listing) Crm 1% ..........................................PSM HYDROCORTISONE (expiry of HSS) Crm 1% .........................................AFT 4.93 7.45 23.49 18.06 28.39 55.90 100 100 100 100 ml 5 5 1% 1% 1% 1% 1% 1% Oct-05 Oct-05 Oct-05 Oct-05 Nov-05 Nov-05 (B) (B) (B) (B) (B) (B)

12.20 2.48

500 g 14.2 g

1% 1%

Sept-08 Sept-05

(B) Cortaid 30 g Derm-Aid 30 g Derm-Aid Soft 30 g Egocort 15 g Egocort 30 g Lipobase Relief 30 g Mildison Lipocream 15 g Pharmacare 15 g Skincalm 15 g (B) (B) (B) (B)

HYDROCORTISONE BUTYRATE (expiry of HSS) Crm 0.1 % ......................................Locoid Cream 5.00 30 g 1% Lipocream 0.1 % ............................Locoid Lipocream 5.00 30 g 1% Lipocream 0.1 % (new listing) ........Locoid Lipocream 15.00 100 g Oint 0.1 % ......................................Locoid Ointment 15.00 100 g 1% Scalp lotn 1% .................................Locoid Lotion 17.90 250 ml 1% Note: Hydrocortisone butyrate scalp lotn (Locoid Lotion) delisted from 1 July 2008 HYOSCINE N-BUTYLBROMIDE (expiry of HSS) Inj 20 mg, 1 ml ...............................Buscopan 7.15 5 1%

Sept-05 Sept-05 Sept-05 Sept-05

Dec-05

(B)

IRON POLYMALTOSE (new listing) Inj 50 mg per ml, 2 ml ....................Ferrum H 20.95 5 1% Sept-08 Ferrosig Note: Ferrosig brand of iron polymaltose inj 50 mg per ml, 2 ml to be delisted from 1 September 2008. METHOTREXTATE (expiry of HSS) Inj 100 mg per ml, 5 ml ..................Methotrexate Ebewe Inj 100 mg per ml, 10 ml ................Methotrexate Ebewe Inj 100 mg per ml, 50 ml ................Methotrexate Ebewe MEROPENEM (new listing) Inj 500 mg......................................Merrem Inj 1 g.............................................Merrem Products with Hospital Supply Status (HSS) are in bold. 18.00 33.00 150.00 1 1 1 1% 1% 1% Jun-06 Jun-06 Jun-06 (B) Mayne Pfizer Mayne Pfizer (B) (B)

255.00 505.00

10 10

1% 1%

Sept-08 Sept-08

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes - effective 1 July 2008 (continued)

METHYLPREDNISOLONE ACETATE (continuation of HSS) Inj 40 mg per ml, 1 ml ....................Depo-Medrol 6.03 1 1% Sept-08 (B)

METHYLPREDNISOLONE ACETATE WITH LIGNOCAINE (continuation of HSS) Inj 40 mg per ml with lignocaine 10 mg per ml, 1 ml ....Depo-Medrol 6.03 1 with Lidocaine METHYLPREDNISOLONE SODIUM SUCCINATE (expiry of HSS) Inj 500 mg......................................Solu-Medrol 16.45 1 Inj 1 g.............................................Solu-Medrol 42.57 1

1% 1% 1%

Sept-08 Sept-05 Sept-05

(B) Baxter Mayne Pharmacia Baxter Mayne Pharmacia Metoclopramide Astra Maxolon Baxter Pfizer AFT Daktarin Fungo Micreme Tinasolve Resolved

METOCLOPRAMIDE HYDROCHLORIDE (New listing) Inj 5 mg per ml, 2 ml ......................Pfizer

4.50

Sept-08

METRONIDAZOLE ( price and continuation of HSS) Inj 500 mg, 100 ml .........................AFT MICONAZOLE NITRATE (new listing) Crm 2 % .........................................Multichem

12.30

Sept-08

0.42

15 g

Sept-08

MORPHINE SULPHATE (expiry of HSS) Inj 10 mg per 10 ml prefilled syringe..........................Biomed Inj 30 mg per 30 ml prefilled syringe..........................Biomed Inj 50 mg per 50 ml prefilled syringe..........................Biomed Inj 60 mg per 30 ml prefilled syringe..........................Biomed Inj 10 mg per ml, 1 ml ....................Mayne Inj 30 mg per ml, 1 ml ....................Mayne MORPHINE TARTRATE (expiry of HSS) Inj 80 mg per ml, 1.5 ml .................Mayne NORADRENALINE ACID TARTRATE (expiry of HSS) Inj 1:1,000 per 2 ml ........................Levophed NORETHISTERONE (new listing) Tab 5 mg........................................Primolut N Products with Hospital Supply Status (HSS) are in bold.

3.55 7.50 5.95 8.75 4.75 5.16 20.20 42.00 25.00

1 1 1 1 5 5 5 6 100

1% 1% 1% 1% 1% 1% 1% 1% 1%

Sept-05 Sept-05 Sept-05 Sept-05 Oct-05 Oct-05 Oct-05 Oct-05 Sept-08

Baxter Baxter Baxter Baxter (B) (B) (B) (B) (B)

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes - effective 1 July 2008 (continued)

NORFLOXACIN (new listing) Tab 400 mg....................................Arrow-Norfloxacin 22.50 NYSTATIN (expiry of HSS) Oral liq 100,000 u per ml ................Nilstat OMEPERAZOLE (new listing) Cap 10 mg .....................................Dr Reddy’s Omeperazole Cap 20 mg .....................................Dr Reddy’s Omeperazole Cap 40 mg .....................................Dr Reddy’s Omeperazole PACLITAXEL (expiry of HSS) Inj 30 mg........................................Taxol Inj 100 mg......................................Taxol Inj 150 mg......................................Paclitaxel Ebewe Inj 300 mg......................................Paclitaxel Ebewe 3.03 2.14 3.05 3.59 100 24 ml 30 30 30 1% Sept-05 Mycostatin

90.00 299.70 461.70 895.85

1 1 1 1

1% 1% 1% 1%

Sept-05 Sept-05 Mar-06 Mar-06

Anzatax Paclitaxel Ebewe Anzatax Paclitaxel Ebewe Anzatax Taxol Taxol

PAMIDRONATE DISODIUM ( price and continuation of HSS) Inj 3 mg per ml, 5 ml ......................Pamisol 18.75 Inj 3 mg per ml, 10 ml ....................Pamisol 37.50 Inj 6 mg per ml, 10 ml ....................Pamisol 75.00 Inj 9 mg per ml, 10 ml ....................Pamisol 112.50 PARACETAMOL (new listing) Oral liquid 120 mg per 5 ml ............Paracare Junior 6.80

1 1 1 1 1000 ml

1% 1% 1% 1% 20%

Sept-08 Sept-08 Sept-08 Sept-08 Sept-08

(B) AFT-Pamidronate AFT-Pamidronate AFT-Pamidronate

Amcal Junior Parapaed Pamol Panadol Colourfree Oral liquid 250 mg per 5 ml ............Paracare 7.00 1000 ml 20% Sept-08 Amcal Double Strength Six Plus Parapaed Pamol PSM Note:Six Plus Parapaed brand of paracetamol oral liquid 250 mg per 5 ml and Junior Parapaed brand of paracetamol oral liquid 120 mg per 5 ml to be delisted from 1 September 2008. PARACETAMOL (expiry of HSS) Suppos 125 mg..............................Panadol Suppos 250 mg..............................Panadol 6.51 12.52 20 20 1% 1% Dec-05 Dec-05 (B) (B)

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes - effective 1 July 2008 (continued)

PENTASTARCH (change of brand name,  price and continuation of HSS) Inf 10% per 500 ml bag ..................StarQuin StarQuin 10% 216.00 16 1% Sept-08 Pentaspan Note: StarQuin (pentastarch inf 10% per 500 ml bag) 1 pack will be delisted from 1 September 2008. PERGOLIDE (new listing) Tab 0.25 mg...................................Permax Tab 1 mg........................................Permax PHENTOALAMINE MESYLATE (expiry of HSS) Inj 10 mg per ml, 1 ml ....................Regitine PHYTOMENADIONE (expiry of HSS) Inj 2 mg per 0.2 ml .........................Konakion MM Inj 10 mg per ml, 1 ml ....................Konakion MM PROCAINE PENICILLIN (expiry of HSS) Inj 1.5 mega u ................................Cilicaine QUINAPRIL (expiry of HSS) Tab 5 mg........................................Accupril Tab 10 mg......................................Accupril Tab 20 mg......................................Accupril RANITIDINE HYDROCHLORIDE (expiry of HSS) Tab 150 mg ...................................Arrow Ranitidine 48.00 170.00 27.50 8.00 9.21 47.60 2.36 3.26 4.30 7.99 100 100 5 5 5 5 30 30 30 250 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% Sept-08 Sept-08 Nov-05 Oct-05 Oct-05 Sept-05 Aug-05 Aug-05 Aug-05 Sept-05 (B) (B) (B) Mayne Aredia (B) (B) (B) (B) Apo-Ranitidine m-Ranitidine Zanidin Zantac Apo-Ranitidine m-Ranitidine Zanidin Zantac

Tab 300 mg....................................Arrow Ranitidine 10.94

250

Sept-05

RECOMBINANT FACTOR VIII Inj 250 IU .......................................Kogenate FS 250.00 ( price) ReFacto 225.00 ( price) Advate 237.50 (new listing) Recombinate 245.00 Inj 500 IU .......................................Kogenate FS 500.00 ( price) ReFacto 450.00 ( price) Advate 475.00 (new listing) Recombinate 490.00 Inj 1,000 IU ....................................Kogenate FS 1,000.00 ( price) Products with Hospital Supply Status (HSS) are in bold.

1 1 1 1 1 1 1 1 1 continued... (B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes - effective 1 July 2008 (continued)

ReFacto 900.00 1 ( price) Advate 950.00 1 (new listing) Recombinate 980.00 1 Inj 1,500 IU (new lisitng).................Advate 1,425.00 1 Inj 2,000 IU ....................................Kogenate FS 2,000.00 1 (new listing) ReFacto 1,800.00 1 ( price) (a) Subject to paragraphs (b) and (c) below: (i) patients receiving Kogenate FS prior to 1 July 2005; (ii) patients commencing treatment with Recombinant Factor VIII after receiving plasma derived Factor VIII; (iii) new patients commencing treatment with Recombinant Factor VIII; (iv) patients undergoing tolerisation with Recombinant Factor VIII; or (v) patients requiring prophylaxis for surgical procedures or in emergency situations and being treated with Recombinant Factor VIII; are required to use Kogenate FS from 1 July 2005. (b) Patients receiving, prior to 1 July 2005, an alternate brand of Recombinant Factor VIII may continue to receive that brand if they continue to tolerate it. (c) Patients whose clinician, for clinical reasons, recommends that the patient receive an alternate brand of Recombinant Factor VIII listed in the Pharmaceutical Schedule may receive that brand. SALBUTAMOL WITH IPRATROPIUM BROMIDE (new listing) Aerosol inhaler, 100 µg with ipratropium bromide, 20 µg per dose ..........................Combivent 13.50 SODIUM BICARBONATE Powder BP(expiry of HSS) ..............Biomed Powder BP (new listing) .................ABM STREPTOKINASE (expiry of HSS) Inj 250,000 IU ................................Streptase Inj 1,500,000 IU .............................Streptase 11.99 9.80 107.00 171.00 continued...

200 dose 500 g 500 g 1 1 100 1% 1% 1% Sept-05 Sept-05 Sept-08 (B) (B) Arrow Lamisil Terbinafin Terbinafine-DP 1% Oct-05 Midwest David Craig

TERBINAFINE (new listing) Tab 250 mg....................................Apo-Terbinafine 25.50

TESTOSTERONE CYPIONATE (new listing and addition of HSS) Inj long-acting 100 mg per ml, 10 ml .............................Depo-Testosterone 61.41 TETRACOSACTRIN (continuation of HSS) Inj 250 µg .....................................Synacthen 177.18 Inj 1 mg per ml, 1 ml ......................Synacthen Depot 26.88

1 10 1

1% 1% 1%

Sept-08 Sept-08 Sept-08

(B) (B) (B)

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes - effective 1 July 2008 (continued)

TRAMADOL HYDROCHLORIDE (expiry of HSS) Cap 50 mg .....................................Tramal Tab sustained release 100 mg ........Tramal Retard Tab sustained release 150 mg ........Tramal Retard Tab sustained release 200 mg ........Tramal Retard Inj 50 mg per ml, 1 ml ....................Tramal 50 Inj 50 mg per ml, 2 ml ....................Tramal 100 TRIAMCINOLONE ACETONIDE (new listing) 0.1% in dental paste USP ................Oracort 2.80 5.60 8.40 11.20 4.50 4.50 4.38 20 20 20 20 5 5 5g 100 1 1% 1% 1% 1% 1% 1% 1% 1% 1% Oct-05 Oct-05 Oct-05 Oct-05 Oct-05 Oct-05 Sept-08 Sept-08 Apr-06 (B) Zytram Zytram Zytram (B) (B) Kenalog in Orabase (B) Abbott Mayne Vancocin

URSODEOXYCHOLIC ACID ( price and continuation of HSS) Cap 300 mg ...................................Actigall 179.00 VANCOMYCIN HYDROCHLORIDE (expiry of HSS) Inj 50 mg per ml, 10 ml ..................Pacific 4.70

Effective 1 June 2008

CEFUROXIME SODIUM ( price and addition of HSS) Inj 750 mg .....................................Zinacef 10.71 5 1% Aug-08 Axetine Pacific Mayne Zilisten Axetine Pacific Mayne Zilisten Mayne Mini-Jet

Inj 1.5 g..........................................Zinacef

4.04

Aug-08

DEXTROSE Inj 50%, 10 ml ................................Biomed HYDROXOCOBALAMIN Inj 1mg per ml, 1 ml .......................ABM LAMOTRIGINE Tab dispersible 25 mg ....................Logem Tab dispersible 50 mg ....................Logem Tab dispersible 100 mg ..................Logem MORPHINE SULPHATE ( price and addition of HSS) Inj 10 mg per ml, 1 ml ....................Mayne Inj 30 mg per ml, 1 ml ....................Mayne RIZATRIPTAN BENZOATE Wafer 10 mg .................................Maxalt Melt

22.75

July-08

9.21 19.38 32.97 56.91 4.50 4.98 25.32

3 56 56 56 5 5 3 1% 1% Aug-08 Aug-08 (B) (B)

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes - effective 1 May 2008

DEXTROSE ( price and addition of HSS) Inj 50%, 10 ml ................................Biomed GLYCERYL TRINITRATE ( price and addition of HSS) TDDS 5 mg ....................................Nitroderm TTS TDDS 10 mg ..................................Nitroderm TTS 22.75 5 1% July-08 Mayne Mini-Jet Minitran Nitrocor Nitro-Dur Minitran Nitrocor Nitro-Dur

16.56 19.60

1% 1%

July-08 July-08

INSULIN PEN NEEDLES 29 g x 12.7 mm..............................ABM 31 g x 6 mm...................................ABM 31 g x 8 mm...................................ABM

11.75 11.75 11.75

100 100 100

INSULIN SYRINGES, DISPOSABLE WITH ATTACHED NEEDLE Syringe 0.3 ml with 29 g x 12.7 mm needle ..............ABM 14.45 Syringe 0.3 ml with 31 g x 8 mm needle ...................ABM 14.45 Syringe 0.5 ml with 29 g x 12.7 mm needle ..............ABM 14.45 Syringe 0.5 ml with 31 g x 8 mm needle ...................ABM 14.45 Syringe 1 ml with 29 g x 12.7 mm needle ..............ABM 14.45 Syringe 1 ml with 31 g x 8 mm needle ...................ABM 14.45 LEFLUNOMIDE ( price) Tab 10 mg......................................AFT-Leflunomide 55.00 Tab 20 mg......................................AFT-Leflunomide 76.00 OMEPRAZOLE ( price) Cap 10 mg ....................................Dr Reddy’s Omeprazole Cap 20 mg .....................................Dr Reddy’s Omeprazole Cap 40 mg .....................................Dr Reddy’s Omeprazole 2.00 2.85 3.35

100 100 100 100 100 100 30 30 28 28 28

RITONAVIR Cap 100 mg ...................................Norvir 121.27 Cap 100 mg ...................................Norvir 242.55 Note – 168 pack size of Norvir to be delisted from 1 May 2008 VENLAFAXINE Cap 37.5 mg ..................................Efexor XR 18.64

84 168

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes - effective 1 May 2008 (continued)

VERAPAMIL HYDROCHLORIDE Tab 80 mg .....................................Verpamil Verpamil tab 80 mg to be delisted from 1 May 2008 6.00 100

Effective 1 April 2008

There are no changes to Section H for 1 April 2008.

Section H changes to Part IV

Effective 1 July 2008

THALIDOMIDE Tab (s25) 100 mg Indefinate supply Tab (s29) 100 mg Bachet’s Disease Penn Grüthenthal

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Index

Pharmaceuticals and brands A ABM Hydroxocobalamin ..................................... 15 Acetic acid with 1, 2- propanediol diacetate and benzethonium ........................................... 28 Advate ......................................................... 45, 46 Accu-Chek Advantage ........................................ 33 Accupril ............................................................. 45 Acetopt .............................................................. 34 Acetylcysteine.................................................... 35 Actigall .................................................. 18, 25, 47 AFT-Leflunomide .......................................... 30, 48 AFT-Pyrazinamide .............................................. 24 Alfacalcidol ........................................................ 19 Allerid C ............................................................. 39 Allopurinol.......................................................... 38 Alpha tocopheryl acetate .................................... 19 Alprazolam ......................................................... 34 Aminoacid formula with minerals without phenylalanine ............................................ 28, 37 Aminoacid formula without methionine ............... 27 Aminoacid formula without valine, leucine and isoleucine ................................................. 27 Aminogran Mineral Mix....................................... 37 Amitrip ............................................................... 38 Amitriptyline ....................................................... 38 Amoxycillin ........................................................ 38 Androcur Depot .................................................. 36 Apo-Gliclazide .............................................. 25, 41 Apo-Terbinafine............................................ 26, 46 Aquasun 30+ .................................................... 26 Aquasun Oil Free Faces SPF 30+ ................. 26, 29 Aquasun Sensitive SPF 30+ .............................. 26 Aqueous ............................................................ 38 Arrow-Norfloxacin ........................................ 26, 44 Arrow Ranitidine................................................. 45 Aspirin ......................................................... 28, 36 B Benzydamine hydrochloride................................ 19 Betamethasone valerate ..................................... 25 Beta Cream ........................................................ 25 Beta Ointment .................................................... 25 Bezafibrate ......................................................... 38 Blenoxane .......................................................... 38 Bleomycin sulphate ............................................ 38 Bricanyl ............................................................. 33 Brimonidine tartarate .................................... 27, 38 Budesonide ........................................................ 18 Budesonide with eformoterol ........................ 15, 33 Bupafen ............................................................. 38 Bupivicaine hydrochloride with fentanyl .............. 38 Buscopan .......................................................... 42 C Calcium ....................................................... 15, 38 Calcium Sandoz ........................................... 15, 38 Calcitriol ............................................................ 19 Calcitriol-AFT ..................................................... 19 Calcium folinate ........................................... 27, 39 Calcium Folinate Ebewe................................ 27, 39 Calcium polystyrene sulphonate ......................... 19 Calcium Resonium ............................................. 19 Calsource .................................................... 15, 38 Carbohydrate ..................................................... 23 Carbohydrate and fat supplement ....................... 28 Catapres ............................................................ 40 Catapres-TTS-1 ................................................. 40 Catapres-TTS-2 ................................................. 40 Catapres-TTS-3 ................................................. 40 Cefazolin sodium ............................................... 39 Cefepime hydrochloride...................................... 39 Cefotaxime sodium ............................................ 39 Ceftazidime ........................................................ 39 Ceftriaxone sodium ............................................ 39 Cefuroxime axetil................................................ 26 Cefuroxime sodium ...................................... 28, 47 Cetirizine hydrochloride ...................................... 39 Cilicaine ............................................................. 45 Cipflox ............................................................... 39 Ciprofloxacin ...................................................... 39 Clarac ................................................................ 34 Clarithromycin.................................................... 34 Clindamycin ....................................................... 40 Clomazol...................................................... 25, 40 Clonidine............................................................ 40 Clotrimazole ................................................. 25, 40 Colofac .............................................................. 18 Combantrin ........................................................ 37 Combivent ................................................... 27, 46 Condoms ......................................... 16, 17, 26, 32 Cozaar ......................................................... 16, 28 Cyclizine lactate ................................................. 40 Cyclosporin........................................................ 40 Cyproterone acetate ........................................... 36 Cytotec .............................................................. 18 D Dalacin C ........................................................... 40 Depo-Medrol ...................................................... 43 Depo-Medrol with Lidocaine ............................... 43 Depo-Testosterone............................................. 46 Desmopressin .............................................. 26, 40 Desmopressin PH&T .................................... 26, 40 Dextrose ................................................ 29, 47, 48 Diabetic enteral feed 1kcal/ml ....................... 16, 36 Diatol ................................................................. 36

Index

Pharmaceuticals and brands Diclofenac sodium ............................................. 40 Difflam ............................................................... 19 Diflucortolone valerate ........................................ 37 Dipentum ........................................................... 18 Dipyridamole...................................................... 40 Dr Reddy’s Omeprazole.................... 15, 29, 44, 48 Duocal Super Soluble Powder ............................ 28 Durex Confidence ............................................... 26 E Elemental 028 Extra ........................................... 29 Emulsifying ointment .................................... 25, 40 Econazole nitrate ................................................ 34 Ecreme .............................................................. 34 Efexor XR ..................................................... 17, 48 Enteral feed with fibre 1.5kcal/ml ........................ 37 Enteral/oral feed 1kcal/ml ................................... 29 Entocort CIR ...................................................... 18 ERA ................................................................... 34 Erythromycin lactobionate .................................. 34 Estrofem ............................................................ 30 Ethics Aspirin ............................................... 28, 36 F Fat modified feed................................................ 29 Fat supplement .................................................. 28 Ferrum H...................................................... 15, 42 Fibalip ................................................................ 38 Flucloxacillin sodium .......................................... 41 Flucloxin ............................................................ 41 Fluconazole .................................................. 26, 41 Flucoxin ............................................................. 41 Fludara............................................................... 41 Fludarabine ........................................................ 41 Fludarabine phosphate ....................................... 41 Fluphenazine decanoate ..................................... 41 Fortisip Powder .................................................. 16 Fortum ............................................................... 39 G Gabapentin ........................................................ 21 Gelatin plasma replacer ...................................... 41 Gelofusine.......................................................... 41 Generaid Plus..................................................... 29 Gliclazide ..................................................... 25, 41 Glipizide ............................................................. 41 Glucerna ............................................................ 37 Glucerna RTH .................................................... 36 Glucerna Select .................................................. 16 Glucerna Select RTH .......................................... 16 Glucose blood diagnostic test meter ................... 33 Glucose dehydrogenase ..................................... 33 Gluten free pasta .......................................... 15, 37 Glycerol ............................................................. 27 Glyceryl trinitrate ........................ 15, 29, 32, 41, 48 Gold Knight .................................................. 16, 17 Granocol ............................................................ 33 H Haemacel........................................................... 41 Haldol ................................................................ 42 Haldol Concentrate ............................................. 42 Haloperidol ........................................................ 42 Haloperidol decanoate ........................................ 42 Hamilton Sunscreen ........................................... 26 Heparinised saline .............................................. 15 Hydrocortisone ............................................ 25, 42 Hydrocortisone butyrate ..................................... 42 Hydroxocobalamin ................................. 15, 32, 47 Hyoscine n-butylbromide ................................... 42 Hyprosin ............................................................ 36 Hyzaar ............................................................... 28 I Insulin syringes, disposable with attached needle ......................................... 17, 48 Ibiamox.............................................................. 38 Insulin isophane ................................................. 33 Insulin pen needles....................................... 16, 48 Iron polymaltose .......................................... 15, 42 K Kindergen .......................................................... 29 Kogenate FS................................................. 45, 46 Konakion MM..................................................... 45 L Lamotrigine.................................................. 16, 47 Leflunomide ................................................. 30, 48 Levonorgestrel ................................. 16, 19, 32, 36 Levophed ........................................................... 43 Lifestyles Flared ................................................. 26 Liquigen ............................................................. 28 Locasol.............................................................. 29 Locoid Cream .................................................... 42 Locoid Lipocream .............................................. 42 Locoid Lotion ..................................................... 42 Locoid Ointment................................................. 42 Logem ......................................................... 16, 47 Losartan ................................................ 16, 20, 28 Losartan with hydrochlorothiazide ................ 20, 28 Low calcium infant formula ................................ 29 Lycinate ....................................................... 15, 41 M Marquis Protecta ................................................ 26 Marquis Supalite ................................................ 26 Maxalt Melt .................................................. 16, 47 Maxipime ........................................................... 39 m-Cefazolin ....................................................... 39

Index

Pharmaceuticals and brands MCT oil (Nutricia) ............................................... 28 Mebeverine hydrochloride .................................. 18 Meropenem ....................................................... 42 Merrem .............................................................. 42 Metabolic Mineral Mixture................................... 28 Methotrextate ..................................................... 42 Methotrexate Ebewe ........................................... 42 Methoxsalen ...................................................... 33 Methylcellulose .................................................. 27 Methyl hydroxybenzoate ..................................... 27 Methylprednisolone acetate ................................ 43 Methylprednisolone acetate with lignocaine ........ 43 Methylprednisolone sodium succinate ................ 43 Metoclopramide hydrochloride ..................... 27, 43 Metronidazole .................................................... 43 Micelle E ............................................................ 19 Miconazole nitrate ........................................ 25, 43 Minidiab ............................................................. 41 Minirin ............................................................... 40 Misoprostol........................................................ 18 Mitozantrone ...................................................... 34 Modecate........................................................... 41 Monogen ........................................................... 29 Morphine sulphate............................ 28, 33, 43, 47 Morphine tartrate ................................................ 43 MSUD Maxamaid ............................................... 27 MSUD Maxamum ............................................... 27 Mucilaginous laxatives with stimulants ............... 33 Multivitamins ..................................................... 29 N Nalcrom ............................................................. 18 Naproxen sodium ............................................... 34 Nelfinavir............................................................ 33 Nerisone ............................................................ 37 Nilstat ................................................................ 44 Nipent ................................................................ 27 Nitroderm TTS.............................................. 29, 48 Nitrolingual Pumpspray ...................................... 41 Noradrenaline acid tartrate .................................. 43 Norethisterone ................................................... 43 Norflex ............................................................... 36 Norfloxacin .................................................. 26, 44 Norpress ............................................................ 15 Nortriptyline hydrochloride.................................. 15 Norvir .............................................. 17, 34, 36, 48 Nutrison Energy Multi Fibre................................. 37 Nystatin ............................................................. 44 O Oestradiol .......................................................... 30 Oestradiol valerate........................................ 16, 36 Olsalazine .......................................................... 18 Omeprazole................................ 15, 25, 29, 44, 48 Omezol .............................................................. 25 One-Alpha .......................................................... 19 Onkotrone .......................................................... 34 Oracort ........................................................ 25, 47 Oral elemental feed 0.8kcal/ml............................ 29 Oral feed 1kcal / ml ...................................... 16, 37 Oral supplement 1kcal/ml ................................... 16 Orgran ......................................................... 15, 37 Orphenadrine citrate ........................................... 36 Oxsoralen........................................................... 33 P Paclitaxel ........................................................... 44 Paclitaxel Ebewe ................................................ 44 Paediatric Seravite.............................................. 29 Pamidronate disodium ................................. 26, 44 Pamisol ....................................................... 26, 44 Panadol ............................................................. 44 Pantoprazole ...................................................... 34 Paracare Double Strength ............................. 15, 44 Paracare Junior ............................................ 15, 44 Paracetamol................................................. 15, 44 Paraffin .............................................................. 28 Parvolex ............................................................. 35 Pentastarch........................................................ 45 Pentostatin (deoxycoformycin) ........................... 27 Peptisoothe ........................................................ 18 Pergolide ..................................................... 27, 45 Permax ........................................................ 27, 45 Phentoalamine mesylate..................................... 45 Phytomenadione ................................................ 45 Postinor-1.................................................... 16, 19 Postinor-2.......................................................... 36 Povidone iodine ................................................. 29 Prazosin hydrochloride ....................................... 36 Primolut N.......................................................... 43 Procaine penicillin .............................................. 45 Prochlorperazine ................................................ 36 Progout.............................................................. 38 Progynova ................................................... 16, 36 Protaphane ........................................................ 33 Pyrantel embonate ............................................. 37 Pyrazinamide ..................................................... 24 Pytazen SR ........................................................ 40 Q Quinapril ............................................................ 45 R Ranitidine hydrochloride ............................... 18, 45 Recombinant ............................................... 45, 46 Recombinant factor viii....................................... 45 ReFacto ....................................................... 45, 46

Index

Pharmaceuticals and brands Regitine ............................................................. 45 Resonium-A ....................................................... 19 Respigen ........................................................... 16 Ritonavir .......................................... 17, 34, 36, 48 Rizatriptan benzoate ..................................... 16, 47 Rocaltrol solution ............................................... 19 S Salamol ............................................................. 28 Salbutamol................................................... 16, 28 Salbutamol with ipratropium bromide............ 27, 46 Salicylic acid ................................................ 25, 37 Sandimmun ....................................................... 40 Serenace ........................................................... 42 Sodium bicarbonate ..................................... 27, 46 Sodium cromoglycate ........................................ 18 Sodium polystyrene sulphonate .......................... 19 Solu-Medrol ....................................................... 43 Somac ............................................................... 34 StarQuin............................................................. 45 StarQuin 10% ..................................................... 45 Stelazine ............................................................ 33 Stemetil ............................................................. 36 Streptase ........................................................... 46 Streptokinase ..................................................... 46 Sulphacetamide sodium ..................................... 34 Sulphur .............................................................. 25 Sunscreens, proprietary ............................... 26, 29 Symbicort Rapihaler ........................................... 33 Synacthen.......................................................... 46 Synacthen Depot ................................................ 46 Synflex............................................................... 34 T Taxol ................................................................. 44 Tenoxicam ......................................................... 37 Terbinafine ................................................... 26, 46 Terbutaline sulphate ........................................... 33 Testosterone cypionate ...................................... 46 Tetracosactrin .................................................... 46 Thalidomide ....................................................... 49 Tilcotil ................................................................ 37 Tolbutamide ....................................................... 36 Topiramate......................................................... 22 Tramadol hydrochloride...................................... 47 Tramal ............................................................... 47 Tramal 50 .......................................................... 47 Tramal 100 ........................................................ 47 Tramal Retard .................................................... 47 Triamcinolone acetonide .............................. 25, 47 Trifluoperazine hydrochloride .............................. 33 U Ursodeoxycholic acid ............................. 18, 25, 47 V Valaciclovir .................................................. 17, 33 Valoid (AFT) ....................................................... 40 Valtrex ......................................................... 17, 33 Vancomycin hydrochloride ................................. 47 Vannair .............................................................. 15 Venlafaxine .................................................. 17, 48 Ventolin ............................................................. 28 Verapamil hydrochloride ............................... 36, 49 Verpamil ...................................................... 36, 49 Vigabatrin .......................................................... 22 Viracept ............................................................. 33 Voltaren ............................................................. 40 Voltaren Optha ................................................... 40 Vosol ................................................................. 28 W Water ................................................................. 34 X Xanax................................................................. 34 XMET Maxamum ................................................ 27 Z Zinacef ......................................................... 28, 47 Zinc and castor oil .............................................. 15 Zinnat ................................................................ 26 Ziprasidone ........................................................ 20

Pharmaceutical Management Agency Level 14, Cigna House, 40 Mercer Street, PO Box 10-254, Wellington 6143, New Zealand Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz Freephone Information line (9am-5pm weekdays) 0800 66 00 50

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.

Metadata

Title

Schedule Update - effective 1 July 2008

Abstract

Pharmaceutical Management Agency Update New Zealand Pharmaceutical Schedule Effective 1 July 2008 Cumulative for May, June, and July 2008 Contents Summary of PHARMAC decisions effective 1 July 2008 … 3 Various restrictions removed from some Alimentary Tract and Metabolism medicines…

Page 1

Note

This text has been extracted from the source PDF document.

Also available as plain text.

Please contact webmaster to discuss alternative format options.